Novel USP7 inhibitors for treating multiple myeloma

JP2023164918A5Inactive Publication Date: 2024-11-14DANA FARBER CANCER INSTITUTE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023142246
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-09-26
Filing Date
2023-09-01
Publication Date
2024-11-14
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current USP7 inhibitors exhibit moderate potency, low selectivity, and high toxicity, limiting their effectiveness in treating malignancies such as multiple myeloma, breast cancer, neuroblastoma, glioma, and ovarian cancer.

Method used

Development of novel compounds, represented by Formula (I), which are potent, selective, and soluble USP7 inhibitors, designed to modulate USP7 activity and target specific diseases by inhibiting its function.

Benefits of technology

The novel compounds effectively inhibit USP7, offering therapeutic benefits in treating cancer, neurodegenerative diseases, immune disorders, and other conditions by reducing toxicity and improving selectivity and solubility compared to existing inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2023164918000001
    Figure 2023164918000001
  • Figure 2023164918000002
    Figure 2023164918000002
  • Figure 2023164918000003
    Figure 2023164918000003
Patent Text Reader

Abstract

To provide a pharmaceutical composition suitable for use in a subject in the treatment or prevention of a disorder associated with modulation of USP7.SOLUTION: The present disclosure relates to inhibitors of USP7 useful in treatment of cancers and other USP7 mediated diseases. In certain embodiments, the present invention provides a pharmaceutical composition suitable for use in a subject in the treatment or prevention of a disorder associated with modulation of USP7 comprising an effective amount of any of compounds (e.g., a compound of the invention, such as a compound of formula (I)) and one or more pharmaceutically acceptable excipients. (In the formula, R1 to R4 are H, halogen, alkyl, or the like; R5 is H, halogen, CN, or the like; and R6 is alkyl or the like.)SELECTED DRAWING: Figure 3C
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related applications This application claims the benefits of U.S. Provisional Patent Application No. 62 / 563,375, filed on 26 September 2017. The contents of this application are incorporated herein by reference in their entirety.

[0002] Description of rights This invention was made with government support under Grant RO1 CA211681, awarded by the National Institutes of Health. The U.S. Government has certain rights to this invention. [Background technology]

[0003] Over the past 5-10 years, deubiquitinating enzymes (DUBs) have attracted considerable attention as drug targets. Because DUB family members stabilize oncogenic proteins, DUB inhibitors effectively promote the degradation of oncogenic proteins, particularly those directly targeted. Therefore, highly optimized and well-defined DUB inhibitors have been extensively searched for. However, many reported DUB inhibitors are multipharmacological agents with weak (micromolar) efficacy against primary targets, limiting their usefulness in target validation and mechanism studies. Due to the lack of high-resolution DUB-small molecule ligand complex structures, no attempts at optimization based on structural information regarding mammalian DUBs have been reported.

[0004] The DUB enzyme USP7 has been shown to be involved in regulating countless cellular processes, including epigenetics, the cell cycle, DNA repair, immunity, viral infection, and tumorigenesis. USP7, also known as herpesvirus-associated ubiquitin-specific protease (HAUSP), was first discovered as a protein that plays a role in viral lytic growth (Everett et al., Novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J, 16, 1997, 566-77). If USP7 is involved in regulating the degradation of the tumor suppressor p53, interest in the enzyme has increased due to its stabilization of the major E3 ligase for p53, MDM2 (Li et al., Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature, 416, 2002, 648-53; Cummins et al., Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature, 428, 2004, 1p following 486; Li et al., A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell, 13, 2004, 879-86). Consistent with its modulation of diverse substrates and biological processes, USP7 has emerged as a drug target in a wide range of malignancies, including multiple myeloma, breast cancer, neuroblastoma, glioma, and ovarian cancer (Chauhan et al., A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma). cells and overcomes bortezomib resistance. Cancer Cell, 22, 2012, 345-58; Wang et al., J Clin Invest, 126, 2016, 2205-20; Tavana et al., Nat Med, 22, 2016, 1180-1186; Cheng et al., Expression of HAUSP in gliomas correlates with disease progression and survival of patients. Oncol Rep, 29, 2013, 1730-6; Zhang et al., Expression of USP7 and MARCH7 Is Correlated with Poor Prognosis in Epithelial Ovarian Cancer. Tohoku J Exp Med, 239, 2016, 165-75). However, known USP7 inhibitors have been shown to exhibit moderate efficacy against USP7 and low selectivity against DUB. The reported drawbacks of known USP7 inhibitor compounds include low solubility and general toxicity, along with moderate potency and selectivity (Chen et al., Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors. Bioorg Med Chem Lett, 27, 2017, 845-849). Therefore, there is a need for the development of more potent, selectively soluble USP7 inhibitors with reduced toxicity. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Everett et al.,Novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein.EMBO J,16,1997,566-77 [Non-Patent Document 2] Li et al.,Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization.Nature,416,2002,648-53 [Non-Patent Document 3] Cummins et al.,Tumour suppression:disruption of HAUSP gene stabilizes p53.Nature,428,2004,1p following 486 [Non-Patent Document 4] Li et al.,A dynamic role of HAUSP in the p53-Mdm2 pathway.Mol Cell,13,2004,879-86 [Non-Patent Document 5] Chauhan et al.,A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Cancer Cell,22,2012,345-58 [Non-Patent Document 6] Wang et al.,J Clin Invest,126,2016,2205-20 [Non-Patent Document 7] Tavana et al.,Nat Med,22,2016,1180-1186 [Non-Patent Document 8] Cheng et al.,Expression of HAUSP in gliomas correlates with disease progression and survival of patients.Oncol Rep,29,2013,1730-6 [Non-Patent Document 9] Zhang et al.,Expression of USP7 and MARCH7 Is Correlated with Poor Prognosis in Epithelial Ovarian Cancer.Tohoku J Exp Med,239,2016,165-75 [Non-Patent Document 10] Chen et al.,Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors.Bioorg Med Chem Lett,27,2017,845-849 [Overview of the project]

[0006] Equation (I) [ka] (In the formula, R1 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NO2, -NH2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s, R2 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NH2, -NO2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s, R3 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy The formula is xy, -OH, -NH2, -NO2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s, R4 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NO2, -NH2, CN, NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s, where R1, R2, R3 and R4 are not simultaneously H, R5 is H, halogen, -CN, -OR7 or -NR7R8, and R6 is alkyl, -C(=O)R 10 -C(=S)R 10 -C(O)NR7R8, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, and each of the above cycloalkyl, heterocycloalkyl, aryl, and heteroaryl can independently be one or more R 11 The alkyl group is optionally substituted with one or more R 12 Substituted with, each R7 and R8 independently is H, alkenyl or alkyl, and each R9 independently in each generation is -NR7R8, alkoxy, -(OCH2CH2) mis alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein the alkyl and alkoxy are each independently optionally substituted with one or more substituents selected from alkoxy, haloalkoxy, halogen and -OH, and the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -N3 and -OH, R 10 is alkyl, alkenyl, alkynyl, -NR7R8, cycloalkyl, heterocycloalkyl, aryl, amino, heteroalkyl, alkylamino, aminoalkyl or heteroaryl, wherein the alkyl, alkenyl and alkynyl are each independently optionally substituted with one or more R 13 and the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each independently optionally substituted with one or more R 12 , each R 11 is independently at each occurrence alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -NO2 or -OH, each R 12 is independently at each occurrence aryl or heteroaryl, wherein the aryl and heteroaryl are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen and -OH, each R 13 is independently at each occurrence -OH, alkoxy, heteroalkoxy, aryloxy, -NH2, arylalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-aryl, -O-heteroaryl, -NR7aryl, -NR7heteroaryl or -NR7C(=O)R 14 , wherein the cycloalkyl, heterocycloalkyl, aryl, heteroalkyl and heteroaryl are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -NO2 and -OH, R 14is alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each of the above aryl and heteroaryl is independently one or more R 15 The alkyl, alkenyl, and alkynyl atoms are optionally substituted with one or more substituents selected from halogens and -OH atoms, and each R 15 R6 is independently a halogen, alkyl, CN-C(=O)alkyl or -C(=O)alkenyl in each generation, and each alkyl and alkenyl is independently substituted with one or more substituents selected from halogen and -OH, m is 1, 2 or 3, and n is 0 or 1, provided that (i) R2 is -NO2, -NHC(O)Me or -NH2 and R1, R2 and R4 are each H, or R1 is Me and R2, R3 and R4 are each H, then R6 is -C(O)R 10 Instead, in the formula, R 10 (ii) is -(CH2)-(CHMe)-phenyl, (ii) R2 is Cl, R1, R3 and R4 are H respectively, and R6 is -C(=O)R 10 And R 10 is one R 13 If it is a (C2-C3) alkyl substituted with, 13 (iii) If R2 is Cl and R1, R3 and R4 are each H, then R6 is -C(=O)R 10 And R 10 Compounds of (other than 1-ethylpropyl) or pharmaceutically acceptable salts thereof are disclosed herein.

[0007] In certain embodiments, the present invention provides a pharmaceutical composition suitable for use on subjects in the treatment or prevention of disorders related to the modification of USP7, comprising an effective amount of any of the compounds described herein (e.g., compounds of the present invention such as the compound of formula (I)) and one or more pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical may be used to treat or prevent symptoms or diseases as described herein.

[0008] A method for inhibiting USP7 is disclosed herein, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject.

[0009] Disclosed herein are methods for treating diseases and conditions that benefit from the modification of USP7, comprising administering to a subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the diseases and conditions benefit from the inhibition of USP7. These diseases and conditions include, but are not limited to, cancer and cancer metastasis, neurodegenerative diseases, immunodeficiencies, diabetes, bone and joint diseases, osteoporosis, arthritis, cardiovascular diseases, ischemic diseases, viral infections and diseases, and viral and / or latent bacterial infections and diseases.

[0010] A method for treating cancer is disclosed herein, comprising administering to a subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is multiple myeloma.

[0011] Compounds of formula (I) or pharmaceutically acceptable salts thereof are disclosed herein, which are used in the manufacture of agents for treating diseases or conditions associated with the inhibition of USP7.

[0012] The use of compounds of formula (I) or pharmaceutically acceptable salts thereof in the treatment of diseases or conditions associated with the inhibition of USP7 is disclosed herein. In certain embodiments, for example, the following are provided: (Item 1) Equation I [ka] (wherein R1 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NO2, -NH2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s.) R2 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NH2, -NO2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl, or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s. R3 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NH2, -NO2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl, or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s. R4 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NO2, -NH2, CN, NR7C(=O)alkyl, -C(=O)NR7alkyl, or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s. However, R1, R2, R3, and R4 are not H at the same time. R5 is H, halogen, -CN, -OR7, or -NR7R8. R6 is alkyl, -C(=O)R 10 -C(=S)R 10 , -C(O)NR7R8, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, Each of the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl molecules independently comprises one or more R 11 It is arbitrarily replaced with, The alkyl group is one or more R 12 Replaced by, Each of R7 and R8 is independently H, alkenyl, or alkyl. Each R9 independently undergoes generation, resulting in -NR7R8, alkoxy, and -(OCH2CH2). m Alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, The alkyl and alkoxy elements are each independently optionally substituted with one or more substituents selected from alkoxy, haloalkoxy, halogen, and -OH groups. The cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -N3, and -OH. R 10 These are alkyl, alkenyl, alkynyl, -NR7R8, cycloalkyl, heterocycloalkyl, aryl, amino, heteroalkyl, alkylamino, aminoalkyl, or heteroaryl. Each of the alkyl, alkenyl, and alkynyl molecules is independently one or more R 13 It is arbitrarily replaced with, The cycloalkyl, heterocycloalkyl, aryl, and heteroaryl each independently comprises one or more R 12 It is arbitrarily replaced with, Each R 11 In each generation, the elements are independently alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -NO2, or -OH. Each R 12 In each generation, it is independently either aryl or heteroaryl. The aryl and heteroaryl compounds are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, and -OH groups. Each R 13 In each generation, independently, -OH, alkoxy, heteroalkoxy, aryloxy, -NH2, arylalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-aryl, -O-heteroaryl, -NR7aryl, -NR7heteroaryl, or -NR7C(=O)R 14 And, The cycloalkyl, heterocycloalkyl, aryl, heteroalkyl, and heteroaryl are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -NO2, and -OH. R 14These are alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl. Each of the aryl and heteroaryl compounds independently comprises one or more R 15 It is arbitrarily replaced with, The alkyl, alkenyl, and alkynyl atoms are each independently optionally substituted with one or more substituents selected from halogens and -OH groups. Each R 15 In each generation, the elements are independently a halogen, an alkyl, a CN-C(=O)alkyl, or a -C(=O)alkenyl. The alkyl and alkenyl molecules are each independently substituted with one or more substituents selected from halogens and -OH groups. m is 1, 2, or 3. n is either 0 or 1. However, (i) if R2 is -NO2, -NHC(O)Me, or -NH2, and R1, R2, and R4 are each H, or if R1 is Me, and R2, R3, and R4 are each H, then R6 is -C(O)R 10 Instead, in the formula, R 10 is -(CH2)-(CHMe)-phenyl, (ii) R2 is Cl, R1, R3 and R4 are H, and R6 is -C(=O)R 10 And R 10 is one R 13 If it is a (C2-C3) alkyl substituted with, 13 It is not unsubstituted cyclopentyl, unsubstituted phenyl, or unsubstituted 2-thiophenyl, (iii) If R2 is Cl and R1, R3 and R4 are H, then R6 is -C(=O)R 10 And R 10 Compounds of (not 1-ethylpropyl) or pharmaceutically acceptable salts thereof. (Item 2) The compounds listed in item 1, wherein R1 is H, -NR7C(=O) alkyl, or -NR7R8. (Item 3) A compound as described in item 1 or 2, wherein R1 is H. (Item 4) A compound described in any one of items 1 to 3, wherein R3 is H, -NO2, or -NR7R8. (Item 5) A compound described in any one of items 1-4, wherein R3 is H. (Item 6) A compound described in any one of items 1 to 5, wherein R4 is H. (Item 7) Each R9 independently undergoes generation, resulting in -NR7R8, alkoxy, and -(OCH2CH2). m They are alkyl, heterocycloalkyl, or heteroaryl. The compound according to any one of items 1 to 6, wherein each heterocycloalkyl or heteroaryl is independently optionally substituted with one or more substituents selected from alkyl, alkoxy, and -N3. (Item 8) A compound listed in any one of items 1 to 7, where n is 0. (Item 9) A compound listed in any one of items 1 to 7, where n is 1. (Item 10) The aforementioned compound is of formula (Ia) [ka] A compound or a pharmaceutically acceptable salt thereof, having the structure of item 1. (Item 11) A compound according to any one of items 1 to 10, wherein R2 is selected from halogen, -NH2, -NO2, CN, -NR7C(=O), and -C(=O)NR7 alkyl, and in the formula, each alkyl is independently optionally substituted with one or more R9s. (Item 12) A compound described in any one of items 1 to 11, wherein R2 is nitro or -NH alkyl. (Item 13) A compound listed in any one of items 1 to 11, wherein R2 is a halo. (Item 14) A compound listed in any one of items 1 to 11, wherein R2 is chloro. (Item 15) A compound according to any one of items 1 to 11, wherein R2 is -NR7C(=O)alkyl or -C(=O)NR7alkyl, and the alkyl group is substituted with one R9. (Item 16) The compounds described in item 15, wherein R9 is heterocycloalkyl or heteroaryl. (Item 17) The compounds listed in item 16, wherein R9 is N-methylpiperazinyl, piperidinyl, or morpholinyl. (Item 18) The compound listed in item 16, in which R9 is imidazolyl. (Item 19) The compound listed in item 15, in which R9 is an azide. (Item 20) The compound described in item 15, wherein R9 is -NR7H. (Item 21) The compounds listed in item 15, wherein R7 is an acyl, alkylacyl, or alkenylacyl. (Item 22) R7 [ka] The compound described in item 21. (Item 23) The aforementioned compound is of formula (Ib) [ka] A compound or a pharmaceutically acceptable salt thereof, having the structure of any one of items 1 to 17. (Item 24) A compound described in any one of items 1 to 23, wherein R5 is H, CN, -OH, or -NR7R8. (Item 25) A compound described in any one of items 1 to 23, wherein R5 is -OH or -NR7R8. (Item 26) R5 is -OH, -NH2, -N(H)CH3, or -N(CH3)2. A compound listed in any one of items 1 through 23. (Item 27) A compound described in any one of items 1 to 26, wherein R5 is -OH. (Item 28) R6 is alkyl, -C(=O)R 10 -C(=S)R 10 A compound described in any one of items 1 to 27, which is aryl or heteroaryl. (Item 29) R6 is -C(=O)R 10 A compound described in any one of items 1 to 28. (Item 30) R 10 The compounds described in item 28 or 29, wherein is alkyl, alkenyl, amino, alkylamino, alkynyl, cycloalkyl, cycloalkyl, alkylamino, heteroaryl, or aminoalkyl. (Item 31) R 10 A compound listed in item 30, wherein the compound is heteroalkyl. (Item 32) The compound according to item 31, wherein the aryl or heteroaryl is further substituted with alkyl, halo, alkyloxy, or nitro. (Item 33) The compound according to item 31, wherein the aryl or heteroaryl is further substituted with a halo, alkyloxy, or nitro. (Item 34) The compound according to item 31, wherein the acylamino is substituted with a halo, alkenyl, heteroaryl, or heterocycloalkyl group. (Item 35) The compound according to item 34, wherein the heteroaryl or heterocycloalkyl is substituted with alkylacyl, alkenylacyl, or hydroxyl. (Item 36) R 10 Each of the following is one or more R 13A compound as described in any one of items 1 to 29, which is optionally substituted with alkyl, alkenyl, alkynyl, -NR7R8, cycloalkyl, or heterocycloalkyl. (Item 37) Each R 13 In each generation, independently, -OH, alkoxy, aryloxy, -NH2, arylalkyl, cycloalkyl, aryl, heteroaryl, or -NR7C(=O)R 14 The compound described in item 36. (Item 38) Each R 14 The compounds described in item 37, in each generation, are independently alkyl, haloalkyl, arylalkyl, alkenyl, heterocyclyl, or heteroaryl. (Item 39) R2 is Cl, -NO2, -NH2, or -NR7C(=O) alkyl. The alkyl group is optionally substituted with one or more R9 groups. R6 is -C(=O)R 10 And, R 10 The elements are alkyl, alkenyl, cycloalkyl, and heterocycloalkyl, where each of the alkyl, alkenyl, and alkynyl elements is independently one or more R 13 It is arbitrarily replaced with, The cycloalkyl and heterocycloalkyl groups each contain one or more R 12 The compounds listed in item 10, which are optionally substituted with the above. (Item 40) Formula (Ib) [ka] (wherein R1 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NO2, -NH2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s.) R2 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NH2, -NO2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl, or -R7R8, where each alkyl is independently optionally substituted with one or more R9s. R3 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NH2, -NO2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl, or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s. R4 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NO2, -NH2, CN, NR7C(=O)alkyl, -C(=O)NR7alkyl, or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s. However, R1, R2, R3, and R4 are not H at the same time. R5 is H, halogen-CN, -OR7, or -NR7R8. R6 is alkyl, -C(=O)R 10 -C(=S)R 10 , -C(O)NR7R8, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, Each of the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl molecules independently comprises one or more R 11 It is arbitrarily replaced with, The aforementioned alkyl group is one or more R 12 Replaced by, Each of R7 and R8 is independently H or alkyl. Each R9 independently undergoes generation, resulting in -NR7R8, alkoxy, and -(OCH2CH2). m Alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, The alkyl and alkoxy elements are each independently optionally substituted with one or more substituents selected from alkoxy, haloalkoxy, halogen, and -OH groups. The cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -N3, and -OH. R 10 These are alkyl, alkenyl, alkynyl, -NR7R8, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. Each of the alkyl, alkenyl, and alkynyl molecules is independently one or more R 13 It is arbitrarily replaced with, The cycloalkyl, heterocycloalkyl, aryl, and heteroaryl each independently comprises one or more R 12 It is arbitrarily replaced with, Each R 11 In each generation, the elements are independently alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -NO2, or -OH. Each R 12 In each generation, it is independently either aryl or heteroaryl. The aryl and heteroaryl compounds are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, and -OH groups. Each R 13 In each generation, independently, -OH, alkoxy, aryloxy, -NH2, arylalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-aryl, -O-heteroaryl, -NR7aryl, -NR7heteroaryl, or -NR7C(=O)R 14 And, The cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, -NO2, and -OH. R 14 These are alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl. Each of the aryl and heteroaryl compounds independently comprises one or more R 15 It is arbitrarily replaced with, The alkyl, alkenyl, and alkynyl atoms are each independently optionally substituted with one or more substituents selected from halogens and -OH groups. Each R 15 In each generation, the elements are independently a halogen, an alkyl, a CN-C(=O)alkyl, or a -C(=O)alkenyl. The alkyl and alkenyl molecules are each independently substituted with one or more substituents selected from halogens and -OH groups. m is 1, 2, or 3. n is either 0 or 1. However, (i) if R2 is -NO2, -NHC(O)Me or -NH2 and R1, R2 and R4 are each H, or if R1 is Me and R2, R3 and R4 are each H, then R6 is -C(O)R 10 Instead, in the formula, R 10 is -(CH2)-(CHMe)-phenyl, (ii) R2 is Cl, R1, R3 and R4 are H, and R6 is -C(=O)R 10 And R 10 is one R 13 If it is a (C2-C3) alkyl substituted with, 13 It is not unsubstituted cyclopentyl, unsubstituted phenyl, or unsubstituted 2-thiophenyl, (iii) If R2 is Cl and R1, R3 and R4 are H, then R6 is -C(=O)R 10 And R 10 Compounds of (not 1-ethylpropyl) or pharmaceutically acceptable salts thereof. (Item 41) A compound selected from the following compounds [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof. (Item 42) A compound selected from the following compounds [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof. (Item 43) A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as described in any one of items 1 to 42, and a pharmaceutically acceptable carrier. (Item 44) A method for treating a disease or disorder as modified in USP7, comprising administering a compound described in any one of items 1 to 42 to a subject in need thereof. (Item 45) A method for inhibiting USP7, comprising administering a compound described in any one of items 1 to 42 to a subject requiring such inhibition. (Item 46) The method according to item 45, wherein the disease or disorder associated with inhibition of USP7 is cancer and cancer metastasis, neurodegenerative disease, immune disorder, diabetes, bone and joint disease, osteoporosis, arthritis, cardiovascular disease, ischemic disease, viral infection and disease, viral infectious and / or latent and bacterial infection and disease. (Item 47) A method for treating cancer, comprising administering a compound described in any one of items 1 to 42 to a subject in need thereof. (Item 48) The method according to item 47, wherein the cancer is liposarcoma, neuroblastoma, glioblastoma, breast cancer, bladder cancer, glioma, neuroblastoma, adrenocortical carcinoma, multiple myeloma, colorectal cancer, non-small cell lung cancer, human papillomavirus-associated cervical, oropharyngeal, penile, ovarian, anal, thyroid, or vaginal cancer, Epstein-Barr virus-associated nasopharyngeal cancer, gastric cancer, rectal cancer, thyroid cancer, Hodgkin lymphoma, or diffuse large B-cell lymphoma. (Item 49) The method according to item 47, wherein the cancer is multiple myeloma, breast cancer, neuroblastoma, glioma, colorectal cancer, prostate cancer, or ovarian cancer. (Item 50) The method described in item 47, wherein the cancer is multiple myeloma. (Item 51) Use of any one of the compounds described in item 1 to 42 for the manufacture of drugs for treating diseases as modified by USP7. (Item 52) A compound described in any one of items 1 through 42, used in the treatment of a disease as regulated by USP7. [Brief explanation of the drawing]

[0013] [Figure 1A] Known compound P22077 and its approximate analog P5091. [Figure 1B] A known USP7 inhibitor. [Figure 2A] Compounds 10 and 11 were derived through optimization based on the structural information of compound A. Compound 11, the enantiomer of compound 10, exhibits 80 times lower activity. [Figure 2B] Dose-dependent inhibition of the catalytic domain (amino acids 208-560) and full-length USP7 (amino acids 1-1102) of USP7 by compounds 10 and 11 using Ub-AMC as a substrate. [Figure 2C] Evaluation of compound 10 that binds to USP7 using isothermal calorimetry. [Figure 2D] Inhibitory activity of compound 10 across a panel of 41 purified DUBs using ubiquitin-rhodamine (Ub-Rho) as a substrate. [Figure 3A] Characteristics of compound 10 that binds to USP7, using a ribbon diagram of compound 10 and USP7. [Figure 3B] A three-dimensional diagram of USP7 (pale blue) bonded to compound 10 (yellow). Hydrogen bonds are indicated by dashed lines. [Figure 3C] Molecular surface representation of the USP7-compound 10 costructure. Highlighted areas indicate altered HDX regions in the presence of compound 10. Dark areas correspond to significant changes, while bright areas correspond to regions with minor changes. [Figure 4A] Analysis of the USP7 mutant protein. Detailed ligand interaction diagram of compound 10 and USP7. Residues containing amino acids belonging to the same class as more than 80% of other USP7s are circled in red. [Figure 4B] Summary of activity against Ub-AMC and inhibition of the USP7 mutant catalytic domain protein by compound A. [Figure 4C] Dose-responsive inhibition of full-length USP7Q351 (amino acids 1-1102) by compound A. [Figure 4D] Dose-responsive inhibition of full-length USP7Q351 (amino acids 1-1102) by compound 10. [Figure 5A] USP7 inhibitory activity and mouse liver microsomal (MLM) stability of the disclosed compounds. [Figure 5B] The structure, USP7 inhibitory activity, and mouse liver microsomal (MLM) stability of the disclosed compound. [Figure 5C] Analysis of the ability of compounds 10 and 11 to bind native USP7 in HEK293T lysate after multiple doses using antagonistic activity-based protein profiling. [Figure 6A] Compound 10 promotes HDM2 loss and accumulation in p53 and p21. Analysis of HDM2, p53, and p21 protein levels in MCF7 cells treated with compound 10 or 11 at specified concentrations for 16 hours. [Figure 6B] Analysis of HDM2, p53, and p21 protein levels in MCF7 cells treated with compound 10 or 11 at specified concentrations for 16 hours, with cycloheximide added for the last 2 hours. [Figure 6C] Analysis of HDM2, p53, and p21 protein levels in MM.1S cells treated with compound 10 or 11 at specified concentrations for 6 hours. [Figure 6D] Analysis of HDM2, p53, and p21 protein levels in MM.1S cells treated with compound 10 or 11 at specified concentrations for 6 hours, with cycloheximide added for the last 2 hours. [Modes for carrying out the invention]

[0014] Equation (I) [ka] (In the formula, R1 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NO2, -NH2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s, R2 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NH2, -NO2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl or -R7R8, where each alkyl is independently optionally substituted with one or more R9s, R3 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy R1 is -OH, -NH2, -NO2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s, R4 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NO2, -NH2, CN, NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s, where R1, R2, R3 and R4 are not simultaneously H, R5 is H, halogen, -CN, -OR7 or -NR7R8, and R6 is alkyl, -C(=O)R 10 -C(=S)R 10 -C(O)NR7R8, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, and each of the above cycloalkyl, heterocycloalkyl, aryl, and heteroaryl can independently be one or more R 11 The alkyl group is optionally substituted with one or more R 12 Substituted with, each R7 and R8 independently is H, alkenyl or alkyl, and each R9 independently in each generation is -NR7R8, alkoxy, -(OCH2CH2) mis alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein each of the alkyl and alkoxy is independently optionally substituted with one or more substituents selected from alkoxy, haloalkoxy, halogen and -OH, and each of the cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -N3 and -OH, R 10 is alkyl, alkenyl, alkynyl, -NR7R8, cycloalkyl, heterocycloalkyl, aryl, amino, heteroalkyl, alkylamino, aminoalkyl or heteroaryl, wherein each of the alkyl, alkenyl and alkynyl is independently optionally substituted with one or more R 13 and each of the cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R 12 and each R 11 is independently, in each occurrence, alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -NO2 or -OH, and each R 12 is independently, in each occurrence, aryl or heteroaryl, wherein each of the aryl and heteroaryl is independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen and -OH, and each R 13 is independently, in each occurrence, -OH, alkoxy, heteroalkoxy, aryloxy, -NH2, arylalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-aryl, -O-heteroaryl, -NR7aryl, -NR7heteroaryl or -NR7C(=O)R 14 and each of the cycloalkyl, heterocycloalkyl, aryl, heteroalkyl and heteroaryl is independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -NO2 and -OH, R 14is alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each of the above aryl and heteroaryl is independently one or more R 15 The alkyl, alkenyl, and alkynyl atoms are optionally substituted with one or more substituents selected from halogens and -OH atoms, and each R 15 R6 is independently a halogen, alkyl, CN-C(=O)alkyl or -C(=O)alkenyl in each generation, and each alkyl and alkenyl is independently substituted with one or more substituents selected from halogen and -OH, m is 1, 2 or 3, and n is 0 or 1, provided that (i) R2 is -NO2, -NHC(O)Me or -NH2 and R1, R2 and R4 are each H, or R1 is Me and R2, R3 and R4 are each H, then R6 is -C(O)R 10 Instead, in the formula, R 10 (ii) is -(CH2)-(CHMe)-phenyl, (ii) R2 is Cl, R1, R3 and R4 are H respectively, and R6 is -C(=O)R 10 And R 10 is one R 13 If it is a (C2-C3) alkyl substituted with, 13 (iii) If R2 is Cl and R1, R3 and R4 are each H, then R6 is -C(=O)R 10 And R 10 Compounds of (other than 1-ethylpropyl) or pharmaceutically acceptable salts thereof are disclosed herein.

[0015] In some embodiments, the compound is of formula (Id) [ka] (In the formula, R1 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NO2, -NH2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s, R2 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NH2, -NO2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl or -R7R8, where each alkyl is independently optionally substituted with one or more R9s, R3 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy R1 is -OH, -NH2, -NO2, CN, -NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s, R4 is H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NO2, -NH2, CN, NR7C(=O)alkyl, -C(=O)NR7alkyl or -NR7R8, where each alkyl is independently optionally substituted with one or more R9s, where R1, R2, R3 and R4 are not simultaneously H, R5 is H, halogen, -CN, -OR7 or -NR7R8, and R6 is alkyl, -C(=O)R 10 -C(=S)R 10 -C(O)NR7R8, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, and each of the above cycloalkyl, heterocycloalkyl, aryl, and heteroaryl can independently be one or more R 11 The alkyl group is optionally substituted with one or more R 12 Substituted with, each R7 and R8 independently is H or alkyl, and each R9 independently in each generation is -NR7R8, alkoxy, -(OCH2CH2) mThe alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is wherein the alkyl and alkoxy are each independently optionally substituted with one or more substituents selected from alkoxy, haloalkoxy, halogen, and -OH, and the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -N3, and -OH, R 10 is alkyl, alkenyl, alkynyl, -NR7R8, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, and each of the alkyl, alkenyl and alkynyl compounds independently comprises one or more R 13 The above cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each independently one or more R 12 It is arbitrarily replaced by each R 11 In each generation, R is independently alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -NO2, or -OH, and each R 12 In each generation, is independently an aryl or heteroaryl, and each of the above aryl and heteroaryl is independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen and -OH, and each R 13 In each generation, independently, -OH, alkoxy, aryloxy, -NH2, arylalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-aryl, -O-heteroaryl, -NR7aryl, -NR7heteroaryl, or -NR7C(=O)R 14 The above cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, -NO2, and -OH, R 14 is alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each of the above aryl and heteroaryl is independently one or more R15 The alkyl, alkenyl, and alkynyl atoms are optionally substituted with one or more substituents selected from halogens and -OH atoms, and each R 15 R6 is independently a halogen, alkyl, CN-C(=O)alkyl or -C(=O)alkenyl in each generation, and each alkyl and alkenyl is independently substituted with one or more substituents selected from halogen and -OH, m is 1, 2 or 3, and n is 0 or 1, provided that (i) R2 is -NO2, -NHC(O)Me or -NH2 and R1, R2 and R4 are each H, or R1 is Me and R2, R3 and R4 are each H, then R6 is -C(O)R 10 Instead, in the formula, R 10 (ii) is -(CH2)-(CHMe)-phenyl, (ii) R2 is Cl, R1, R3 and R4 are H respectively, and R6 is -C(=O)R 10 And R 10 is one R 13 If it is a (C2-C3) alkyl substituted with, 13 (iii) If R2 is Cl and R1, R3 and R4 are each H, then R6 is -C(=O)R 10 And R 10 It is a compound (not 1-ethylpropyl) or a pharmaceutically acceptable salt thereof.

[0016] In some embodiments, R1 is H, -NR7C(=O) alkyl, or -NR7R8. In certain embodiments, R1 is H. In some embodiments, R3 is H, -NO2, or -NR7R8. In certain embodiments, R3 is H. In some embodiments, R4 is H. In some embodiments, each R9 is independently -NR7R8, alkoxy, or -(OCH2CH2) in each generation. mR9 is an alkyl, heterocycloalkyl, or heteroaryl, and each of the heterocycloalkyl or heteroaryl is optionally substituted with one or more substituents selected from alkyl, alkoxy, and -N3. In some embodiments, n is 0, but in other embodiments, n is 1. In some embodiments, R9 is a heterocycloalkyl or heteroaryl. In some embodiments, R9 is N-methylpiperazinyl, piperidinyl, or morpholinyl. In some embodiments, R9 is imidazolyl. In some embodiments, R9 is an azide. In some embodiments, R9 is -NR7H. In some embodiments, R7 is an acyl, alkylacyl, or alkenylacyl. In some embodiments, R7 is [ka] That is the case.

[0017] In some embodiments, R2 is selected from halogens, -NH2, -NO2, CN, -NR7C(=O), and -C(=O)NR7 alkyl groups, where each alkyl group is independently substituted with one or more R9 groups. In certain embodiments, R2 is a halo group such as chloro, fluoro, or bromo. In some embodiments, R2 is chloro. In some embodiments, R2 is -NR7C(=O) alkyl or -C(=O)NR7 alkyl, where the alkyl group is substituted with one R9 group. In some embodiments, R2 is nitro or -NH alkyl.

[0018] In some embodiments, R5 is H, CN, -OH, or -NR7R8. In other embodiments, R5 is -OH or -NR7R8. In certain embodiments, R5 is -OH, -HN2, -N(H)CH3, or -N(CH3)2. In some embodiments, R5 is -OH.

[0019] In some embodiments, R6 is alkyl, -C(=O)R 10 -C(=S)R 10, aryl or heteroaryl. In some embodiments, R6 is -C(=O)R 10 In a particular embodiment, R 10 Each of the following is one or more R 13 The alkyl, alkenyl, alkynyl, -NR7R8, cycloalkyl or heterocycloalkyl is optionally substituted with R. In other embodiments, R 13 In each generation, independently, -OH, alkoxy, aryloxy, -NH2, arylalkyl, cycloalkyl, aryl, heteroaryl, or -NR7C(=O)R 14 In some embodiments, R 14 In each generation, the elements are independently alkyl, haloalkyl, arylalkyl, alkenyl, heterocyclyl, or heteroaryl.

[0020] In some embodiments, R 10 The elements are alkyl, alkenyl, amino, alkylamino, alkynyl, cycloalkyl, cycloalkyl, alkylamino, heteroaryl, or aminoalkyl. In some embodiments, the alkyl, amino, alkylamino, or cycloalkyl is substituted with aryl, aralkyl, heteroaryl, heterocyclyl, acylamino, aryloxy, or hydroxyl. In some embodiments, the aryl or heteroaryl is further substituted with alkyl, halo, alkyloxy, or nitro. In some embodiments, the aryl or heteroaryl is further substituted with halo, alkyloxy, or nitro. In some embodiments, the acylamino is substituted with halo, alkenyl, heteroaryl, or heterocycloalkyl. In some embodiments, the heteroaryl or heterocycloalkyl is substituted with alkylacyl, alkenylacyl, or hydroxyl.

[0021] In some embodiments, R2 is Cl, -NO2, -NH2, or -NR7C(=O)alkyl, where the alkyl is optionally substituted with one or more R9s, and R6 is -C(=O)R 10 And R 10These are alkyl, alkenyl, cycloalkyl, and heterocycloalkyl, and each of the alkyl, alkenyl, and alkynyl is one or more R 13 The cycloalkyl and heterocycloalkyl groups are optionally substituted, and each group consists of one or more R groups. 12 It can be arbitrarily replaced with.

[0022] Formula (Ib) [ka] Compounds of (wherein R2, R5, and R6 are as defined above and herein) or pharmaceutically acceptable salts thereof are also disclosed.

[0023] Formula (Ic) [ka] Compounds of (wherein R5 and R6 are as defined above and herein) or pharmaceutically acceptable salts thereof are also disclosed.

[0024] In some embodiments, the compounds of the present invention are those shown in Table 3 or 4.

[0025] In certain embodiments, the present invention provides a pharmaceutical product suitable for use in human patients, comprising any of the compounds described above (e.g., compounds of the present invention such as the compound of formula (I)) and one or more pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical product may be used to treat or prevent symptoms or diseases as described herein. Any of the disclosed compounds may be used in the manufacture of a pharmaceutical product for the treatment of any disease or symptom disclosed herein.

[0026] Details of the disclosure are given in the accompanying specification below. While similar or equivalent methods and materials may be used in the medical practice or examinations described herein, representative methods and materials are described herein. Other features, purposes, and advantages of this disclosure will become apparent from this specification and the claims. In the specification and the accompanying claims, singular nouns include plural nouns unless specifically indicated otherwise. Unless otherwise defined, all specialized scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this disclosure belongs. All patents and publications cited herein are incorporated herein by reference in their entirety.

[0027] definition Unless otherwise specified, all specialized scientific terms used herein have the meanings that are commonly understood by those skilled in the art. The following references provide general definitions of many terms used herein to those skilled in the art: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). Unless otherwise specified, the following terms have the meanings used herein.

[0028] In this disclosure, “comprises,” “comprising,” “containing,” and “having,” etc., may have their respective meanings under U.S. patent law, and may mean “includes,” “including,” etc. Similarly, “consisting essentially of” or “consists essentially” may have their respective meanings under U.S. patent law, and the term is not scoped to consider the existence of such other things that do not constitute embodiments of the prior art, unless the existence of such other things changes the fundamental or novel features of what is described.

[0029] Unless otherwise specified or evident from the context, the term "or" is understood to be inclusive as used herein. Unless otherwise specified or evident from the context, the terms "a," "an," and "the" are understood to be singular or plural as used herein.

[0030] Unless otherwise indicated, the term “and / or” in this disclosure is used to mean “and” or “or.”

[0031] The term "acyl" is approved in the relevant technical field and refers to a group represented by the general formula hydrocarbyl C(O)-, preferably alkyl C(O).

[0032] The term "acylamino" is approved in the relevant technical field and refers to an amino group substituted with an acyl group, which may be represented, for example, by the formula hydrocarbyl C(O)NH-.

[0033] The term "acyloxy" is approved in the relevant technical field and refers to a group represented by the general formula hydrocarbyl C(O)O-, preferably C(O)O-.

[0034] The term "alkoxy" refers to an alkyl group to which oxygen is bonded, preferably a lower alkyl group. Typical alkoxy groups include methoxy, ethoxy, propoxy, and tert-butoxy groups.

[0035] The term "alkoxyalkyl" refers to an alkyl group substituted with an alkoxy group, and may also be represented by the general formula alkyl-O-alkyl.

[0036] As used herein, the term “alkenyl” means an aliphatic group containing at least one double bond and is intended to include both “unsubstituted alkenyls” and “substituted alkenyls.” The latter refers to an alkenyl moiety having substituents that substitute hydrogens on one or more carbons of the alkenyl group. Such substituents may arise on one or more carbons that are included in or not included in one or more double bonds. Furthermore, such substituents include all possible substituents for alkyl groups, except for those that are extremely stable, as will be discussed below. For example, substitution of alkenyl groups with one or more alkyl groups, carbocykyl groups, aryl groups, heterocyclyl groups, or heteroaryl groups is predicted.

[0037] "Alkyl" or "alkane" are fully saturated linear or branched non-aromatic hydrocarbons. Unless otherwise defined, linear or branched alkyl groups typically have 1 to about 20 carbon atoms, preferably 1 to about 10 carbon atoms. Examples of linear or branched alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, pentyl, and octyl. C1-C6 linear or branched alkyl groups are also called "lower alkyl" groups.

[0038] Furthermore, as used herein, in the examples and claims, the term “alkyl group” (or “lower alkyl group”) is intended to include both “unsubstituted alkyl groups” and “substituted alkyl groups,” the latter meaning an alkyl group having a substituent that substitutes a hydrogen on one or more carbons of a hydrocarbon skeleton. Unless otherwise specified, such substituents may include, for example, halogens, hydroxyls, carbonyls (e.g., carboxyls, alkoxycarbonyls, formyl or acyls), thiocarbonyls (e.g., thioesters, thioacetates or thioformates), alkoxyls, phosphoryls, phosphate esters, phosphonates, phosphinates, aminos, amides, amidines, imines, cyanos, nitros, azides, sulfhydryls, alkylthios, sulfates, sulfonates, sulfonates, sulfamoyls, sulfonamides, sulfonyls, heterocyclyls, aralkyls, or aromatic or heteroaromatic groups. Where appropriate, those skilled in the art will understand that the substituted group on the hydrocarbon chain may itself be substituted. For example, substituents on substituted alkyl groups may include substituted and unsubstituted forms of amino groups, azide groups, imino groups, amide groups, phosphoryl groups (including phosphonic acid esters and phosphinic acid esters), sulfonyl groups (including sulfuric acid esters, sulfonamide groups, sulfamoyl groups and sulfonic acid esters), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylic acid esters and esters), -CF3, -CN, etc. Representative substituted alkyl groups are described below. Cycloalkyl groups can be further substituted with alkyl, alkenyl, alkoxy, alkylthio, aminoalkyl, carbonyl-substituted alkyl groups, -CF3, -CN, etc.

[0039] The term "Cx-y," used with chemical moieties such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy, means a group containing x to y carbon atoms in its chain. For example, the term "Cx-y alkyl" means a substituted or unsubstituted saturated hydrocarbon group containing x to y carbon atoms in its chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, as well as linear and branched alkyl groups. C0 alkyl, when intrinsic, indicates a hydrogen atom where the bond is at the terminal position. The terms "C2-y alkenyl" and "C2-y alkynyl" mean a substituted or unsubstituted unsaturated aliphatic group that contains at least one double or triple bond, but is similar in length and possible substitutions to the alkyl group.

[0040] As used herein, the term "heteroalkyl" means a saturated or unsaturated chain of carbon atoms and at least one heteroatom, in which no two heteroatoms are adjacent.

[0041] Furthermore, as used herein, in the examples and claims, the term “heteroalkyl” (or “lower heteroalkyl”) is intended to include both “unsubstituted heteroalkyl” and “substituted heteroalkyl,” the latter meaning a heteroalkyl moiety having substituents that substitute hydrogens on one or more carbons or heteroatoms of the skeleton. Unless otherwise specified, such substituents may include, for example, halogens, hydroxyls, carbonyls (e.g., carboxyls, alkoxycarbonyls, formyl or acyls), thiocarbonyls (e.g., thioesters, thioacetates or thioformates), alkoxyls, phosphoryls, phosphate esters, phosphonates, phosphinates, aminos, amides, amidines, imines, cyanos, nitros, azides, sulfhydryls, alkylthios, sulfates, sulfonates, sulfonates, sulfamoyls, sulfonamides, sulfonyls, heterocyclyls, aralkyls, or aromatic or heteroaromatic moieties. Where appropriate, those skilled in the art will understand that the moieties substituted on the heteroalkyl chain may themselves be substituted. For example, the substituents of a substituted heteroalkyl group may include substituted and unsubstituted forms of amino groups, azide groups, imino groups, amide groups, phosphoryl groups (including phosphonic acid ester groups and phosphinic acid ester groups), sulfonyl groups (including sulfuric acid ester groups, sulfonamide groups, sulfamoyl groups and sulfonic acid ester groups), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylic acid esters and esters), -CF3, -CN, and the like.

[0042] As used herein, the term "alkylamino" means an amino group substituted with at least one alkyl group.

[0043] As used herein, the term "alkylthio" means a thiol group substituted with an alkyl group, and may be represented by the general formula alkylS-.

[0044] As used herein, the term “alkynyl” means an aliphatic group containing at least one triple bond and is intended to include both “unsubstituted alkynyl” and “substituted alkynyl.” The latter refers to an alkynyl moiety having substituents that substitute hydrogens on one or more carbons of the alkynyl group. Such substituents may arise on one or more carbons that are included in or not included in one or more triple bonds. Furthermore, such substituents include all possible substituents for alkyl groups, except for those that are highly stable as discussed above. For example, substitution of an alkynyl group with one or more alkyl groups, carbocykyl groups, aryl groups, heterocyclyl groups, or heteroaryl groups is predicted.

[0045] The term "amide" as used in this specification means [ka] (In the formula, each R 10 Each of these independently represents either a hydrogen atom or a hydrocarbyl group, or two Rs. 10 This refers to a group that, together with the bonded N atom, forms a heterocycle with 4 to 8 atoms in the ring structure.

[0046] The terms "amine" and "amino" are approved in the relevant technical field and include both unsubstituted and substituted amines and their salts, for example, [ka] (In the formula, each R 10 R independently represents a hydrogen atom or a hydrocarbyl group, or two Rs. 10 This refers to a site that can be represented as (where these, together with the bonded N atom, form a heterocycle having 4 to 8 atoms in the ring structure). The term "aminoalkyl" as used herein means an alkyl group substituted with an amino group.

[0047] As used herein, the term "aralkyl" refers to an alkyl group substituted with an aryl group.

[0048] As used herein, the term "aryl" includes substituted or unsubstituted monocyclic aromatic groups in which each atom of the ring is carbon. The ring is preferably a 5- to 7-membered ring, and more preferably a 6-membered ring. The term "aryl" also includes polycyclic systems having two or more rings in which two or more carbons are common, where at least one of two adjacent rings is aromatic, for example, the other ring may be a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Examples of aryl groups include benzene, naphthalene, phenanthrene, phenol, and aniline.

[0049] The term "carbamate ester" is approved in the relevant technical field. [ka] (In the formula, R9 and R10 independently represent a hydrogen or a hydrocarbyl group such as an alkyl group, or R9 and R10, together with intervening atoms (multiple atoms are possible), form a heterocycle having 4 to 8 atoms in the ring structure.)

[0050] As used herein, the terms “carbocyclic” and “of a carbocyclic” mean a saturated or unsaturated ring in which each atom of the ring is carbon. The term carbocyclic includes both aromatic and non-aromatic carbocyclic rings. Non-aromatic carbocyclic rings include both cycloalkane rings in which all carbon atoms are saturated and cycloalkene rings containing at least one double bond.

[0051] The term "carbocyclic ring" includes 5- to 7-membered monocyclic rings and 8- to 12-membered bicyclic rings. Each ring in a bicyclic carbocyclic ring may be selected from saturated, unsaturated, and aromatic rings. A carbocyclic ring includes a bicyclic molecule in which one, two, or three or more atoms are shared between the two rings of the bicyclic molecule. The term "condensed carbocyclic ring" means a bicyclic carbocyclic ring in which each ring shares two adjacent atoms with the other ring. Each ring in a condensed carbocyclic ring may be selected from saturated, unsaturated, and aromatic rings. In a typical embodiment, an aromatic ring, e.g., phenyl, may be condensed with a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated, and aromatic bicyclic rings that are valence-acceptable is included in the definition of a carbocyclic ring. Typical "carbocyclic rings" include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octa-3-ene, naphthalene, and adamantane. Typical condensed carbocyclic rings include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-1H-indene, and bicyclo[4.1.0]hepta-3-ene. The "carbocyclic rings" may be substituted at any one or more positions where hydrogen atoms can be present.

[0052] The "cycloalkyl" group is a cyclic hydrocarbon that is completely saturated. "Cycloalkyl" includes monocyclic and bicyclic rings. Unless otherwise defined, monocyclic cycloalkyls generally have 3 to about 10 carbon atoms, more commonly 3 to 8 carbon atoms. The second ring of a bicyclic cycloalkyl may be selected from saturated, unsaturated, and aromatic rings. Cycloalkyls include bicyclic molecules in which one, two, or three or more atoms are shared between the two rings of the bicyclic molecule. The term "condensed cycloalkyl" refers to a bicyclic cycloalkyl in which each ring shares two adjacent atoms with the other ring. The second ring of a condensed bicyclic cycloalkyl may be selected from saturated, unsaturated, and aromatic rings. The "cycloalkenyl" group is a cyclic hydrocarbon containing one or more double bonds.

[0053] As used herein, the term "carbocycryl" refers to an alkyl group substituted with a carbocyclic group.

[0054] The term "carbonate ester" is approved in the relevant technical field and refers to a -OCO2-R10 group (wherein R10 represents a hydrocarbyl group).

[0055] As used herein, the term "carboxyl" refers to the group represented by the formula -CO2H.

[0056] As used herein, the term "ester" refers to a -C(O)OR10 group (wherein R10 represents a hydrocarbyl group).

[0057] As used herein, the term "ether" refers to a hydrocarbyl group bonded to one hydrocarbyl group via oxygen. Therefore, the ether substituent of the hydrocarbyl group may be hydrocarbyl-O-. Ethers may be symmetric or asymmetric. Examples of ethers include, but are not limited to, heterocyclic-O-heterocyclic and aryl-O-heterocyclic groups. Ethers may also contain an "alkoxyalkyl" group, which may be represented by the general formula alkyl-O-alkyl.

[0058] As used herein, the terms "halo" and "halogen" mean halogens, including chloro, fluoro, bromo, and iodine.

[0059] As used herein, the terms "hetallalkyl" and "hetallalkyl" refer to alkyl groups substituted with hetalil groups.

[0060] The terms "heteroaryl" and "hetalil" include substituted or unsubstituted aromatic monocyclic structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, where these ring structures contain at least one heteroatom, preferably 1 to 4 heteroatoms, more preferably 1 or 2 heteroatoms. The terms "heteroaryl" and "hetalil" also include polycyclic systems having two or more rings with two or more carbons common to the two rings, where at least one of two adjacent rings is heteroaromatic, for example, the other ring may be a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclil. Examples of heteroaryl groups include pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine.

[0061] As used herein, the term "heteroatom" means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.

[0062] The terms "heterocyclyl," "heterocycle," and "heterocyclic formula" include substituted or unsubstituted non-aromatic monocyclic structures, preferably 3- to 10-membered rings, more preferably 3- to 7-membered rings, where these ring structures contain at least one heteroatom, preferably 1-4 heteroatoms, more preferably 1 or 2 heteroatoms. The terms "heterocyclyl" and "heterocycle" also include polycyclic systems having two or more rings with two or more carbons common to the two adjacent rings, where at least one of the two adjacent rings is a heterocycle, for example, the other ring may be a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Examples of heterocyclyl groups include piperidine, piperazine, pyrrolidine, morpholin, lactone, lactam, and the like.

[0063] As used herein, the term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclic group.

[0064] As used herein, the term "hydrocarbyl" means a group that does not have =O or =S atoms and is linked via carbon atoms that typically have at least one carbon-hydrogen bond and a major carbon skeleton, but may optionally contain heteroatoms. Therefore, groups such as methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl can be considered hydrocarbyl for the purposes of this application, rather than substituents such as acetyl (which has an =O substituent on the linking carbon) and ethoxy (which is linked via oxygen, not carbon). Hydrocarbyl groups include, but are not limited to, aryl, heteroaryl, carbocyclic, heterocyclyl, alkyl, alkenyl, alkynyl, and combinations thereof.

[0065] As used herein, the term "hydroxyalkyl" refers to an alkyl group substituted with a hydroxyl group.

[0066] The term “lower” as used with chemical moieties such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy means that the substituent contains 10 or fewer non-hydrogen atoms, preferably 6 or fewer. “Lower alkyl” means, for example, an alkyl group containing 10 or fewer carbon atoms, preferably 6 or fewer. In certain embodiments, the acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents as defined herein are, respectively, lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, and these groups are represented individually or in combination with other substituents such as hydroxyalkyl and aralkyl (for example, when counting carbon atoms in an alkyl substituent, atoms in an aryl group are not counted) as detailed.

[0067] The terms “polycyclyl,” “polycyclic,” and “polycyclic formula” refer to two or more rings (e.g., cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl) in which two or more atoms are common to two adjacent rings, for example, rings that are “fused rings.” Each ring in a polycyclic compound may or may not be substituted. In certain embodiments, each ring in a polycyclic compound contains 3 to 10, preferably 5 to 7, atoms.

[0068] The term "silyl" refers to the silicon moiety bonded to three hydrocarbyl moieties.

[0069] The term “substituted” refers to a site having a substituent that substitutes a hydrogen on one or more carbon atoms of the skeleton. “Substituted” or “substituted with” is understood to include the implicit conditions that such substituents match the substituted atom and the acceptable valence of the substituent, and that the substitution results in a stable compound, such as one that does not spontaneously undergo transformation by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” may include all acceptable substituents of an organic compound. In a broad range of embodiments, acceptable substituents include acyclic and cyclic branched and unbranched carbocyclic and heterocyclic aromatic and non-aromatic substituents of the organic compound. There may be one or more acceptable substituents, and they may be the same or different for a given organic compound. For the purposes of the present invention, heteroatoms such as nitrogen may have hydrogen substituents and / or any acceptable substituents of the organic compound described herein that satisfy the valence of the heteroatom. Substituents may include some of the substituents described herein, e.g., halogens, hydroxyls, carbonyls (e.g., carboxyls, alkoxycarbonyls, formyls, or acyls), thiocarbonyls (e.g., thioesters, thioacetates, or thioformates), alkoxyls, phosphoryls, phosphates, phosphonates, phosphinates, aminos, amides, amidines, imines, cyanos, nitros, azides, sulfhydryls, alkylthios, sulfates, sulfonates, sulfonates, sulfamoyls, sulfonamides, sulfonyls, heterocyclyls, aralkyls, or aromatic or heteroaromatic moieties. Those skilled in the art will understand that, where appropriate, the substituents themselves may be substituted. Unless specifically stated as “substituted,” references to chemical moieties herein are understood to include substituted isoforms. For example, references to “aryl” groups or moieties implicitly include both substituted and unsubstituted isoforms.

[0070] The term "sulfate ester" is approved in the relevant technical field and refers to the -OSO3H group or any pharmaceutically acceptable salt thereof.

[0071] The term "sulfonamide" is approved in the relevant field and has a general formula [Chemical formula] (In the formula, R9 and R10 independently represent a hydrocarbyl such as hydrogen or alkyl, or R9 and R10 together with optional intervening atom(s) represent a group forming a heterocycle having 4 to 8 atoms in the ring structure).

[0072] The term "sulfoxide" is approved in the art and means a -S(O)-R10 group (wherein R10 represents a hydrocarbyl).

[0073] The term "sulfonic acid ester" is approved in the art and means a SO3H group or a pharmaceutically acceptable salt thereof.

[0074] The term "sulfone" is approved in the art and means a -S(O)2-R10 group (wherein R10 represents a hydrocarbyl).

[0075] The term "thioalkyl" as used herein means an alkyl group substituted with a thiol group.

[0076] The term "thioester" as used herein means a -C(O)SR10 group or a -SC(O)R10 group (wherein R10 represents a hydrocarbyl group).

[0077] The term "thioether" used in the present invention is equivalent to an ether, and the oxygen is replaced by nitrogen. <了

[0078] The term "urea" is approved by the art and has the general formula [Chemical formula] (In the formula, R9 and R10 independently represent a hydrocarbyl such as hydrogen or alkyl, or together with R10, the presence of R9 and optional intervening atom(s) form a heterocycle having 4 to 8 atoms in the ring structure).

[0079] The term "protecting group" refers to an atomic group that, when bonded to a reactive functional group of a molecule, shields, reduces, or inhibits the reactivity of that functional group. Generally, protecting groups may be selectively removed during the course of synthesis as desired. Examples of protecting groups can be found in Greene and Wuts, *Protective Groups in Organic Chemistry*, 3. rd This can be found in Ed., 1999, John Wiley & Sons, NY and Harrison et al., Compendium of Synthetic Organic Methods, Vols. 1-8, 1971-1996, John Wiley & Sons, NY. Typical nitrogen protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl ("CBZ"), tert-butoxycarbonyl ("Boc"), trimethylsilyl ("TMS"), 2-trimethylsilyl-enanthulfonyl ("TES"), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl ("FMOC"), and nitroveratyloxycarbonyl ("NVOC"). Typical hydroxyl protecting groups include, but are not limited to, those in which the hydroxyl group is acylated (esterified) or alkylated, such as benzyl and trityl ethers, alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers (e.g., TMS or TIPS groups), ethylene glycol and propylene glycol derivatives, and glycol ethers such as allyl ethers.

[0080] The term “prodrug” is intended to encompass compounds that are converted under physiological conditions to the therapeutic activators of the present invention (e.g., compounds of formula I). ​​A common method for creating a prodrug is to hydrolyze under physiological conditions to include one or more selected sites that exhibit the desired molecule. In other embodiments, the prodrug is converted by the enzyme activity of the subject. For example, preferred prodrugs of the present invention are esters or carbonates (e.g., esters or carbonates of alcohols or carboxylic acids). In certain embodiments, some or all of the compounds of formula I in the formulations shown above can be replaced with corresponding preferred prodrugs, for example, prodrugs in which the hydroxyl group in the parent compound exists as an ester, or in which the carbonate or carboxylic acid present in the parent compound exists as an ester.

[0081] The present invention encompasses all pharmaceutically acceptable isotope-labeled compounds used herein, in which one or more atoms are replaced with atoms having the same atomic number but an atomic mass or mass number different from that typically observed. In certain embodiments, the compounds of the present invention are concentrated in such isotope-labeled substances (e.g., compounds in which the distribution of isotopes in the compound in the composition differs from the natural or typical distribution of isotopes).

[0082] Examples of isotopes suitable for inclusion in the compounds of the present invention include: 2 H and 3 Hydrogen such as H, 11 C, 13 C and 14 Carbon such as C, 36 Chlorine such as Cl 18 Fluorine such as F 123 I and 125 Iodine such as I 13 N and 15 Nitrogen such as N, 15 O, 17 O and 18 Oxygen such as O, 32 Phosphorus such as P, and 35 Examples include sulfur isotopes such as S.

[0083] Certain isotope-labeled compounds disclosed herein, for example, those incorporating radioisotopes, are useful in drug and / or substrate tissue distribution studies. Radioisotopes such as tritium, i.e. 3 H and carbon-14, that is 14 C is useful for this purpose in terms of ease of implementation and rapid detection.

[0084] Deuterium, that is 2 Substitution with heavy isotopes such as H may be preferable in some situations because it can provide certain therapeutic benefits through higher metabolic stability, such as increased half-life in vivo or reduced dose requirements.

[0085] 11 C, 18 F, 15 O and 13 Substitution with positron-emitting isotopes such as nitrate (N) may be useful in positron emission tomography (PET) studies to investigate substrate acceptor occupancy.

[0086] The compounds of the present invention may have one or more chiral carbon atoms and may exist in the form of optically pure enantiomers, mixtures of enantiomers, for example, racemic compounds, optically pure diastereoisomers, mixtures of diastereoisomers, racemic compounds of diastereoisomers, or mixtures of racemic compounds of diastereoisomers. For example, optically active forms can be obtained by asymmetric synthesis or resolution of racemic compounds by asymmetric chromatography (chromatography using chiral adsorbents or eluents). That is, some of the disclosed compounds may exist in the form of various stereoisomers.

[0087] Stereoiomers are compounds that differ only in their stereoconfiguration. Enantiomers are pairs of stereoisomers that are not mirror images of each other, as they most commonly contain an asymmetrically substituted carbon atom that acts as a chiral center. "Enantiomer" means one of a pair of molecules that are mirror images of each other and cannot be superimposed. "Diastereomer" is a stereoisomer that is not mirror-image related, as it most commonly contains two or more asymmetrically substituted carbon atoms and represents the arrangement of substituents around one or more chiral carbon atoms. Enantiomers of a compound can be prepared by separating the enantiomer from a racemic compound using one or more known techniques and methods, such as chiral chromatography and separation methods based thereon. Those skilled in the art can easily determine appropriate techniques and / or methods for separating the enantiomers of the compounds described herein from a racemic compound mixture.

[0088] "Geometric isomers" refer to isomers in which the orientation of substituent atoms differs in relation to a carbon-carbon double bond, cycloalkyl ring, or bridging bicyclo system. The atoms at each end of the carbon-carbon double bond (other than H) may be in either an E configuration (substituent is on the opposite side of the carbon-carbon double bond) or a Z configuration (substituent is oriented on the same side). "R", "S", "S * "R *"E", "Z", "cis", and "trans" indicate the configuration relative to the core molecule. Some of the disclosed compounds may exist in the form of atropisomers. Atropisomers are stereoisomers resulting from rotational hindrance around a single bond, where the steric strain hindrance to rotation is high enough to allow for the isolation of conformosomers. The compounds of the present invention may be prepared as individual isomers by isomer-specific synthesis or by reduction from an isomer mixture. Conventional decomposition techniques include forming salts of the free bases of each isomer of an isomer pair using optically active acids (followed by fractional crystallization and regeneration of the free bases), forming salts of the acidic forms of each isomer of an isomer pair using optically active amines (followed by fractional crystallization and regeneration of the free acids), forming esters or amides of the respective isomers of an isomer pair using optically pure acids, amines, or alcohols (followed by chromatographic separation and removal of chiral auxiliaries), or separating the isomer mixture of the starting material or the final product using various well-known chromatographic methods.

[0089] Weight-based diastereomer purity is the weight of one diastereomer or a ratio to the weight of all diastereomers combined. If the stereochemistry of a disclosed compound is named or shown from its structure, the named or shown stereoisomer is at least about 60% by weight, about 70% by weight, about 80% by weight, about 90% by weight, about 99% by weight, or about 99.9% by weight relative to other stereoisomers. If a single enantiomer is named or shown from its structure, the named or shown enantiomer is optically pure at least about 60% by weight, about 70% by weight, about 80% by weight, about 90% by weight, about 99% by weight, or about 99.9% by weight. If a single diastereomer is named or shown from its structure, the named or shown diastereomer is pure at least about 60% by weight, about 70% by weight, about 80% by weight, about 90% by weight, about 99% by weight, or about 99.9% by weight. The percentage of optical purity is expressed as the weight of the enantiomer or as the ratio of the weight of the enantiomer to the weight of its optical isomer.

[0090] The percentage of purity based on mole fraction is the ratio of moles of an enantiomer (diastereomer) or the ratio of moles of an enantiomer (diastereomer) to moles of its optical isomer. If the stereochemistry of a disclosed compound is named or shown from its structure, the named or shown stereoisomer is at least about 60 mol%, about 70 mol%, about 80 mol%, about 90 mol%, about 99 mol%, or about 99.9 mol% relative to the other stereoisomers. If a single enantiomer is named or shown from its structure, the named or shown enantiomer is optically pure at least about 60 mol%, about 70 mol%, about 80 mol%, about 90 mol%, about 99 mol%, or about 99.9 mol%. If a single diastereomer is named or indicated by its structure, the named or indicated diastereomer is pure at least about 60 mol%, about 70 mol%, about 80 mol%, about 90 mol%, about 99 mol%, or about 99.9 mol%.

[0091] Without mentioning stereochemistry, if a disclosed compound is named or shown from its structure and the compound has at least one chiral center, it should be understood that the name or structure encompasses enantiomers of the compound that do not contain the corresponding optical isomer, racemic mixtures of the compound, or mixtures that are abundant in one enantiomer of the corresponding optical isomer. Without mentioning stereochemistry, if a disclosed compound is named or shown from its structure and has two or more chiral centers, it should be understood that the name or structure encompasses diastereomers that do not contain other diastereomers, many diastereomers that do not contain a pair of other diastereomers, mixtures of diastereomers, mixtures of diastereomer pairs, mixtures of diastereomers in which one diastereomer is abundant in other diastereomers, or mixtures of diastereomers in which one or more diastereomers are abundant in other diastereomers. The present invention encompasses all of these forms.

[0092] As used herein, the term “pharmaceutically acceptable salt” means any pharmaceutically acceptable salt of the compound of formula (I). For example, any pharmaceutically acceptable salt of any of the compounds described herein is within the range of reliable medical judgment suitable for use in contact with human and animal tissues without excessive toxicity, irritation, or allergic response, and corresponds to a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977 and in Pharmaceutical Salts: Properties, Selection, and Use, (Eds. PHStahl and CGWermuth), Wiley-VCH, 2008. Such salts may be prepared in situ at the time of final isolation, during the purification of the compounds described herein, or separately by a reaction of a free base with a suitable organic acid.

[0093] The compounds of the present invention may have ionic groups that allow for preparation as pharmaceutically acceptable salts. These salts may be acid addition salts containing inorganic or organic acids, or, in the case of the acidic form of the compounds of the present invention, these salts may be prepared from inorganic or organic bases. The compounds are frequently prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases, as well as methods for preparing suitable salts, are well known in the art. The salts may be prepared from pharmaceutically acceptable non-toxic acids and bases, including inorganic and organic acids and bases.

[0094] Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, laurylsulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, citrate, thiocyanate, toluenesulfonate, undecanoate, and valerate. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine, including but not limited to non-toxic ammonium, quaternary ammonium, and amine cations.

[0095] The term "subject" for which administration is contemplated includes mammals, including humans (i.e., males or females of any age group, such as pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or elderly adults)) and / or other primates (e.g., cynomolgus monkeys, monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, cats, and / or dogs, and / or birds, including commercially relevant birds such as chickens, ducks, geese, quails, and / or turkeys, but not limited thereto. Preferred subjects are humans.

[0096] As used herein, “preventive” therapeutic for a disease or symptom means a compound that, for a statistical sample, reduces the incidence or delays the onset of a disease or symptom in a treated sample compared to an untreated control sample, or reduces the severity of one or more symptoms of a disease or symptom compared to an untreated control sample.

[0097] In treatment, the objective is to prevent or slow (reduce) undesirable physiological symptoms, impairments, or diseases, or to obtain beneficial or desired clinical outcomes. Beneficial or desired clinical outcomes include, but are not limited to, relief of symptoms, reduction of the extent of symptoms, impairments, or diseases, stabilization (i.e., no worsening) of symptoms, impairments, or diseases, delay or slowing of the onset of progression of symptoms, impairments, or diseases, improvement of detectable or undetectable symptoms, impairments, or diseases or remission (partial or complete), improvement of at least one measurable physical parameter or enhancement or improvement of symptoms, impairments, or diseases, which may not necessarily be identifiable by the patient. Treatment includes inducing a clinically significant response without excessive levels of side effects. Treatment also includes extending life compared to the expected survival without treatment.

[0098] How to use Ubiquitin is a 76-amino acid protein that, post-translation, is bound to a substrate protein via the formation of an isopeptide bond between the C-terminal glycine of ubiquitin and the substrate lysine side chain. Linear and branched polyubiquitin chains are constructed via the binding of one of the seven lysines of another molecule of ubiquitin or to the N-terminal methionine of ubiquitin (Pickart and Fushman, Curr Opin Chem Biol, 8, 610-6, 2004). Ubiquitin is bound to substrate proteins through the coordinated action of ubiquitin-activating (E1), conjugation (E2), and ligation (E3) enzymes and is removed by known families of proteases as deubiquitinating enzymes (DUB). The first recognized role of the ubiquitin system was the regulation of protein turnover (Lecker et al., J Am Soc Nephrol, 17, 1807-19, 2006). Ubiquitin tags are also responsible for signaling a wide range of non-degradable functions (O'Neill, J Biol Chem, 284, 8209, 2009). Ubiquitination can influence protein activity by modulating conformational changes, complexation with other proteins, sensitivity to the addition of other post-translational modifications (PTMs), including phosphorylation and acetylation, and cellular localization. Through complex degradation and non-degradable functions, ubiquitination coordinates a wide range of cellular processes, including proteolysis, DNA repair, chromatin remodeling, receptor signaling, and immunity (Pinto-Fernandez and Kessler, Front Genet, 7, 133, 2016). Unsurprisingly, abnormal ubiquitin system activity is associated with disease, the most severe cancers, infection, and neurodegeneration (D'Arcy et al.). al.,Pharmacol Ther,147,32-54,2015;Atkin and Paulson, Front Mol Neurosci, 7, 63, 2014; Nanduri et al., Curr Pharm Des, 19, 3234-47, 2013). Deregulation of the ubiquitin-proteasome system is associated with cancer (Hoeller Ubiquitin has been linked to the pathogenesis of many human diseases, including neurodegenerative disorders (Rubinsztein, Nature 2006, 443(7113), 780-786) and viral diseases (Gao & Luo Can J Physiol Pharmacol 2006, 84(1), 5-14). The relationship between ubiquitin and cancer biology was clinically validated with the FDA approval of the proteasome inhibitor bortezomib for multiple myeloma (Kane et al., Oncologist, 8, 508-13, 2003).

[0099] There are approximately 100 human duoproteins (DUBs) belonging to six different families. Five of these families [ubiquitin-specific proteases (USP), ubiquitin C-terminal hydrolase (UCH), ovarian tumor protease (OTU), Josephin, and Mindy] are cysteine ​​proteases, while the sixth family [JAB / MPN / MOV34 (JAMM / MPN)] consists of zinc metalloproteinases (Komander et al., Nat Rev Mol Cell Biol, 10, 550-63, 2009; Clague et al., Physiol Rev, 93, 1289-315, 2013; Abdul Rehman). (et al., Mol Cell, 63, 146-55, 2016). Many DUBs have been associated with physiological and / or pathophysiological functions. Ubiquitin-specific proteases and ubiquitin C-terminal hydrolase (UCH) enzymes are among the most characteristic members of the DUB family (Komander et al. 2009; Nijman et al. Cell 2005, 123(5), 773-786). For example, USP1 and USP4 are involved in DNA damage repair (Kee and Huang, Mol Cell Biol, 36, 524-44, 2015). USP22 and BAP1 play a role in chromatin function (Atanassov et al., FEBS Lett, 585, 2016-23, 2011), while USP2 and USP8 have been reported to stabilize the oncogenic protein cyclin D1 (Shan et al., 2009) and mutant EGFR (Byun et al., Clin Cancer Res, 19, 3894-904, 2013), respectively. From the X-ray crystal structure of the catalytic core of each family, it is clear that all except the Mindy family adopt a common fold consisting of three domains. In these three domains, the finger domain coordinates the ubiquitin core, and the thumb and palm coordinate the ubiquitin tail in the active site containing the three catalytic structures (Komander et al., 2009). While numerous apo-type ubiquitins and ubiquitin-binding structures have been analyzed, analyses using non-ubiquitin compounds are extremely rare. In particular, there are no reports of small molecule DUB complex structures for mammalian USP families with up to 56 members (Komander et al., 2009), (Davies et al., Bioorg Med Chem Lett, 22, 3900-4, 2012; Ratia et al., Proc Natl Acad Sci USA, 105, 16119-24, 2008; Schlierf et al., Nat Commun, 7, 13166, 2016).

[0100] Generally, while duovalent bisphosphonates (DUBs) are considered a class targeted for drug development, inhibitor development is still in its early stages. The first DUB inhibitor, the duovalent USP14 / UCHL5 inhibitor VLX1570, entered clinical trials in 2015 (Wang et al., Sci Rep, 6, 26979, 2016b). DUB inhibitors, this one targeting the SARs DUB PLPro (Baez-Santos et al., Antiviral Res, 115, 21-38, 2015), are the only example of development incorporating the structure of a DUB inhibitor, with an IC50 lower than 500 nM. 50s This resulted in the production of compounds exhibiting high selectivity for mammalian DUB. In this case, the selectivity may be due to significant structural differences between viral and mammalian DUB. However, no examples of optimization incorporating the structure of mammalian DUB have been reported. A breakthrough in X-ray crystallography of small molecule DUB inhibitor conjugates could enable the rapid development of potent and selective inhibitors.

[0101] USP7 (ubiquitin-specific protease 7) / HAUSP (herpesvirus-associated ubiquitin-specific protease) is a 135 kDa protein in the USP family. USP7 has been shown to interact with viral proteins such as ICP0 (Vmw 110), an inhibitor that stimulates the pre-early genes of herpes simplex virus in the viral lytic cycle (Everett et al., J Virol 73, 1999, 417-426), and EBNA1 (Epstein-Barr Nuclear Antigen-1) (Holowaty et al., J Biol Chem 2003, 278, 29987-29994 and 47753-47761). USP7 has been shown to be involved in regulating a multitude of cellular processes, including epigenetics, cell cycle, DNA repair, immunity, viral infection, and tumorigenesis. When USP7 is shown to regulate the degradation of the tumor suppressor p53 (Li et al., Nature, 416, 648-53, 2002), interest in the enzyme increased by stabilizing the major E3 ligase MDM2 for p53 (Cummins et al., Nature, 428, 1 p following 486, 2004, Li et al., Mol Cell, 13, 879-86, 2004). Recent reports have consistently shown that USP7 silencing also increases steady-state p53 levels by promoting Mdm2 degradation. More recently, it has been shown that the binding of USP7 to p53 is regulated by TSPYL5, a protein potentially involved in thoracic carcinogenesis through competition with p53 that binds to the same region of USP7 (Epping et al., Nat Cell Biol. 2011, 13(1):102-8). More recently, upward and downward regulation of USP7 has been shown to inhibit in vitro colon cancer cell proliferation and in vivo tumor growth by resulting in constitutively high p53 levels (Becker et al. Cell Cycle 2008, 7(9), 1205-13).

[0102] USP7 uses P16 via Bmi1 / Mel18 stabilization. INK4aIt also alters the levels of tumor suppressor factors (Maertens et al., Embo J. 2010 29, 2553-2565). Additional proteins involved in genomic integrity / regulation, such as DNMT1 DNA methylase and classpin adapters, are also stabilized by USP7 (Du et al., Science Signaling 2010, 3(146):ra80; Faustrup et al., J. Cell Biol. 2009, 184(1):13-9). The presence of USP7 and DNMT1, a protein involved in maintaining epigenetic methylation necessary for arresting genes involved in progression and cancer expression, is importantly correlated in human colorectal cancer (Du et al., 2010). USP7 has been shown to deubiquitinate the well-known major repressor gene PTEN in human cells, inducing PTEN to be transported out of the nucleus and subsequently inactivated (Song et al., Nature 2008, 455(7214), 813-7). USP7 overexpression was first reported in prostate cancer, and it is even more significant that this overexpression is directly associated with tumor aggressiveness (Song et al., Nature 2008, 455(7214), 813-7).

[0103] In recent years, methyltransferase PHF8 (Wang et al., 2016a) and demethylase DNMT1 (Du et al., 2010, Felle et al., Nucleic Acids Res, 39, 8355-65, 2011, Qin et al.) have been studied. Various epigenetic modifiers, including the acetyltransferase Tip60 (Dar et al., Mol Cell Biol, 33, 3309-20, 2013), as well as H2B itself (van der Knaap et al., Mol Cell, 17, 695-707, 2005), have been identified as direct targets of USP7. Other notable targets of USP7 include the transcription factor FOXP3 (van Loosdregt et al., Immunity, 39, 259-71, 2013), which links this DUB enzyme to the immune response in Treg cells, and N-Myc, which stabilizes it in neuroblastoma cells (Tavana et al., Nat Med, 22, 1180-1186, 2016). In line with its regulatory mechanisms and biological processes across diverse substrates, USP7 has emerged as a drug target in a wide range of malignancies, including multiple myeloma (Chauhan et al., Cancer Cell, 22, 345-58, 2012), breast cancer (Wang et al., 2016a), neuroblastoma (Tavana et al., 2016), glioma (Cheng et al., Oncol Rep, 29, 1730-6, 2013), and ovarian cancer (Zhang et al., Tohoku J Exp Med, 239, 165-75, 2016). USP7 has been shown to deubiquitinate FOXO4 in human cells, inducing its export and subsequent inactivation, which in turn activates the oncogenic PI3K / PKB signaling pathway (van der Horst et al., Nat Cell Biol. 2006, 8, 1064-1073). Ultimately, USP7 plays a crucial role in p53-mediated cellular responses to various stresses, including DNA damage and oxidative stress (Marchenko et al., Embo J. 2007 26, 923-934, Meulmeester et al., Mol Cell 2005, 18, 565-576, van der Horst et al., Nat Cell Biol. 2006, 8, 1064-1073).

[0104] Multiple myeloma (MMz) is an incurable hematological malignancy characterized by the accumulation of abnormal plasma cells in the bone marrow that interfere with the production of normal blood cells. While the average survival of MM patients has improved in recent years as a result of the introduction of proteasome inhibitors and immunomodulatory therapy regimens, it remains quite low, only after 5 years. The proteasome inhibitor bortezomib identifies the ubiquitin proteasome as a therapeutic target for MM drug development. USP7 is a therapeutic target for MM due to its role in p53 degradation. USP7 is highly expressed in tumor cells of MM patients and in MM cell lines versus normal bone marrow cells. Mutations or deletions of p53 are terminal phenomena in MM, suggesting that increased p53 levels due to pharmacological inhibition of USP7 may be an effective therapeutic strategy for this malignancy.

[0105] P22077 and its approximate analog P5091 (structure shown in Figure 1A) are the most frequently used inhibitors to investigate USP7 function. P22077 exhibits moderate potency against USP7 (IC50 = 8.0 μM), as well as equipotent inhibition of two additional DUBs, USP10 and USP47 (Altun et al., 2011, Ritorto). (et al., 2014). Reported drawbacks of these nitrothiophene compounds include low solubility and general toxicity, along with moderate potency and selectivity (Chen et al., 2017). Although it does not possess superior characteristics compared to P5091 / P22077, additional USP7 inhibitors (shown in Figure 1B) have been identified, and no significant optimization attempts have been made (Reverdy et al., Chem Biol, 19, 467-77, 2012; Colland et al., Mol Cancer Ther, 8, 2286-95, 2009; Aleo et al., Cancer Res, 66, 9235-44, 2006; Nicholson et al., Protein Sci, 17, 1035-43, 2008; Yamaguchi et al., Bioorg Med Chem Lett, 23, 3884-6, 2013; Tanokashira et al., Tetrahedron, 72, 5530-5540, 2016).

[0106] Disclosed herein are methods for treating and preventing diseases and conditions that benefit from the regulation of USP7, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

[0107] Disclosed herein are methods for treating and preventing diseases and conditions that benefit from inhibition of USP7, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

[0108] A method for inhibiting USP7, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject requiring such inhibition, is disclosed herein.

[0109] In certain embodiments, methods for treating a disease or disorder modulated with USP7, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, are disclosed herein. In certain embodiments, methods for preventing a disease or disorder modulated with USP7, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, are disclosed herein. In some embodiments, the modulation of USP7 is associated with inhibiting USP7.

[0110] In one embodiment, the disease or disorder is selected from cancer and cancer metastasis, neurodegenerative diseases, immune disorders, diabetes, bone and joint diseases, osteoporosis, arthritis disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectious and / or latent and bacterial infections and diseases.

[0111] Disclosed herein is the use of USP7 inhibitors for the preparation of agents for treating or preventing diseases or conditions modulated with USP7, wherein the agent comprises a compound of formula (I). In some embodiments, the modulation of USP7 is associated with inhibiting USP7.

[0112] Compounds of formula (I) used to treat diseases or conditions modulated by USP7 are disclosed herein. In some embodiments, the modulation of USP7 is associated with inhibiting USP7.

[0113] A method for treating cancer, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, is disclosed herein.

[0114] In some embodiments, representative cancers include, but are not limited to, liposarcoma, neuroblastoma, glioblastoma, breast cancer, bladder cancer, glioma, neuroblastoma, adrenocortical carcinoma, multiple myeloma, colorectal cancer, non-small cell lung cancer, human papillomavirus-associated cervical, oropharyngeal, penile, ovarian, anal, thyroid, or vaginal cancer, Epstein-Barr virus-associated nasopharyngeal cancer, gastric cancer, rectal cancer, thyroid cancer, Hodgkin lymphoma, or diffuse large B-cell lymphoma.

[0115] In some embodiments, the cancer is selected from multiple myeloma, breast cancer, neuroblastoma, glioma, colorectal cancer, prostate cancer, neuroblastoma, and ovarian cancer. In some embodiments, the cancer is breast cancer, glioma, neuroblastoma, multiple myeloma, or ovarian cancer. In some embodiments, the cancer is multiple myeloma.

[0116] A method for treating neuroblastoma, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, is disclosed herein.

[0117] In some embodiments, neurodegenerative diseases include, but are not limited to, Alzheimer's disease, multiple sclerosis, Huntington's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, amyotrophic lateral sclerosis, or encephalitis.

[0118] Pharmaceutical composition The compositions and methods of the present invention can be used to treat subjects in need of treatment. In certain embodiments, the subjects are mammals such as humans or non-human mammals. When administered to subjects such as humans, the compositions or compounds are preferably administered as a pharmaceutical composition comprising, for example, the compounds of the present invention and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water, physiological buffer salts or other solvents, vehicles such as glycols, oils such as glycerin or olive oil, or injectable organic esters. In preferred embodiments, when such pharmaceutical compositions are for human administration, particularly for invasive administration routes (i.e., routes that avoid transport or diffusion across the epithelial barrier, such as injection or insertion), the aqueous solutions are free of or substantially free of pyrogens. Excipients can be selected, for example, to delay the release of the drug or to selectively target one or more cells, tissues or organs. Pharmaceutical compositions may be in unit dosage forms such as tablets, capsules (including small capsules and gelatin capsules), granules, reconstituted hydrophilic agents, powders, solutions, syrups, suppositories, and injections. The composition may also be included in transdermal delivery systems, such as skin patches. It may also be included in solutions suitable for topical administration, such as eye drops.

[0119] A pharmaceutically acceptable carrier may contain a physiologically acceptable agent that acts to stabilize, improve, or increase the solubility of a compound, such as the compound of the present invention. Such physiologically acceptable agents include, for example, sugars such as glucose, sucrose, or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, or other stabilizers or excipients. The selection of a pharmaceutically acceptable carrier containing a physiologically acceptable agent depends, for example, on the route of administration of the composition. The formulation or pharmaceutical composition may be a self-emulsifying drug delivery system or a self-microemulsifying drug delivery system. The pharmaceutical composition (formulation) may also be a liposome or other polymer matrix, which can be incorporated into the composition, and may be, for example, the compound of the present invention. For example, liposomes containing phospholipids or other lipids are non-toxic, physiologically acceptable, and metabolizable carriers that are relatively easy to manufacture and administer.

[0120] The term "pharmaceutically acceptable" as used herein means the above-mentioned compounds, materials, compositions and / or dosage forms that are suitable for use in contact with the target tissue without excessive toxicity, irritation, allergic response or other problem or difficulty, in proportion to a reasonable benefit / risk ratio, within the bounds of reliable medical judgment.

[0121] As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier “must be” acceptable in the sense that it is compatible with the other components of the formulation and must not be harmful to the subject. Some examples of materials that can function as pharmaceutically acceptable carriers include: (1) sugars such as lactose, glucose, and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) tragacanth powder; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository wax; and (9) peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil. Examples include oils such as (10) glycols such as propylene glycol, (11) polyols such as glycerin, sorbitol, mannitol and polyethylene glycol, (12) esters such as ethyl oleate and ethyl laurate, (13) agar, (14) buffering agents such as magnesium hydroxide and aluminum oxide, (15) alginic acid, (16) water free of pyrogens, (17) isotonic saline, (18) Ringer's solution, (19) ethyl alcohol, (20) phosphate buffer, and (21) other non-toxic compatible substances used in pharmaceutical formulations.

[0122] For example, a pharmaceutical composition (formulation) can be administered to a target by several routes of administration, including, for example, orally (e.g., an aqueous or non-aqueous solution or suspension for application to the tongue, tablets, capsules (including small capsules and gelatin capsules), bolus, powder, granules, paste, etc.), absorbed through the oral mucosa (e.g., sublingually), anally, rectally, or vaginally (e.g., as a pessary, cream, or foam), parenterally (e.g., intramuscularly, intravenously, subcutaneously, or subarachnoidally as a sterile solution or suspension), nasally, intraperitoneally, subcutaneously, percutaneously (e.g., as a patch applied to the skin), and topically (e.g., as a cream, ointment, spray, or eye drop applied to the skin). The compound may be prepared for inhalation. In certain embodiments, the compound may simply be dissolved or suspended in sterile water. Details of suitable administration routes and compositions suitable for such administration can be found, for example, in U.S. Patents 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, and the patents described therein.

[0123] The formulations can be conveniently presented in single dosage forms and may be prepared by any method well known in the field of pharmacy. The amount of active ingredient that can be combined with the carrier material for producing a single dosage form varies depending on the subject being treated and the specific method of administration. Generally, the amount of active ingredient that can be combined with the carrier material for producing a single dosage form is the amount of the compound that produces the therapeutic effect. Of 100%, this amount is usually about 1% to about 99%, preferably about 5% to about 70%, and most preferably about 10% to about 30% of the active ingredient.

[0124] Methods for preparing these formulations or compositions include the step of combining an active compound, such as the compound of the present invention, with a carrier and optionally one or more minor components. Generally, the formulation is prepared by uniformly and intimately combining the compound of the present invention with a liquid carrier or a finely divided solid carrier, or both, and, if necessary, subsequently forming a product.

[0125] Formulations of the present invention suitable for oral administration may be in the form of capsules (including small capsules and gelatin capsules), cachets, pills, tablets, confectionery tablets (using flavored main ingredients, usually sucrose and gum arabic or tragacanth), hydrophilic preparations, powders, granules, or as solutions or suspensions in aqueous or non-aqueous liquids, as oil-in-water or water-in-oil liquid emulsions, as elixirs or syrups, as lozenges (using inert main ingredients such as gelatin and glycine or sucrose and gum arabic), and / or as mouthwashes, etc. Each of these contains a predetermined amount of the compound of the present invention as an active ingredient. The composition or compound may be administered as a bolus, lick, or paste.

[0126] To prepare solid dosage forms for oral administration (capsules (including small capsules and gelatin capsules), tablets, pills, sugar-coated tablets, powders, granules, etc.), one or more pharmaceutically acceptable carriers such as sodium citrate or dicalcium phosphate, and / or (1) fillers or bulking agents such as starch, lactose, sucrose, glucose, mannitol and / or silicic acid, (2) binders such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and / or gum arabic, (3) wetting agents such as glycerin, (4) agar, calcium carbonate, potato The active ingredient is mixed with any of the following: (5) a disintegrant such as molasses or tapioca starch, alginic acid, certain silicates and sodium carbonate; (6) a dissolution retarder such as paraffin; (7) an absorption enhancer such as quaternary ammonium compounds; (8) a wetting agent such as cetyl alcohol and glycerol monostearate; (9) an absorbent such as kaolin and bentonite clay; (10) a lubricant such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate and mixtures thereof; (11) a complexing agent such as modified and unmodified cyclodextrin; and a coloring agent. In the case of capsules (including small capsules and gelatin capsules), tablets and pills, the pharmaceutical composition may also contain a buffer. Similar types of solid compositions may be used as fillers in soft and hard gelatin capsules using lactose or milk sugar and excipients such as high molecular weight polyethylene glycol.

[0127] Tablets may be formed by compression or molding with one or more auxiliary components as desired. Compressed tablets may be prepared using binders (e.g., gelatin or hydroxypropyl methylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium glycolate starch or cross-linked carboxymethylcellulose sodium), surfactants, or dispersants. Wet formulations may be formed by molding a mixture of powdered compounds moistened with an inert liquid diluent using appropriate machinery.

[0128] Tablets, as well as other solid dosage forms of pharmaceutical compositions such as sugar-coated tablets, capsules (including small capsules and gelatin capsules), pills, and granules, may optionally be slit or prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulation field. These may be formulated to give a slow or controlled release of the active ingredient therein, for example, by using hydroxypropyl methylcellulose to vary the proportion of other polymer matrices, liposomes, and / or microparticles that provide desired release properties. These may be sterilized, for example, by filtration with a bacterial-retaining filter or by incorporating a sterilizer in the form of a sterile solid component that can be dissolved in sterile water or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifiers and may have a composition that releases only the active ingredient(s) or preferentially in a delayed manner in a predetermined part of the gastrointestinal tract. Examples of embedding compositions that can be used include polymers and waxes. The active ingredient may, where appropriate, be in the form of microencapsulated with one or more of the above excipients.

[0129] Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, reconstituted hydrophilic substances, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage form may contain, for example, water or other solvents, suiclotextrin and its derivatives, solubilizers, and inert diluents commonly used in the art, such as emulsifiers including ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrorulyl alcohol, polyethylene glycol, and sorbitan fatty acid esters, and mixtures thereof.

[0130] In addition to inert diluents, oral compositions may also contain auxiliary agents such as humectants, emulsifiers and suspending agents, sweeteners, flavoring agents, colorants, fragrances, and preservatives.

[0131] In addition to the active compound, the suspension may also contain suspending agents, such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methhydroxyl, bentonite, agar and tragacanth, and mixtures thereof.

[0132] Pharmaceutical compositions for rectal, vaginal, or urethral administration may be presented as suppositories. These suppositories may be prepared by mixing one or more active compounds with one or more suitable non-irritating excipients or carriers, such as cocoa butter, polyethylene glycol, suppository wax, or salicylates, which are solid at room temperature but become liquid at body temperature, and thus melt in the rectum or vaginal cavity, releasing the active compounds.

[0133] The formulation of the orally administered pharmaceutical composition may be presented as a mouthwash, oral spray, or oral ointment.

[0134] Alternatively, or in addition, the composition may be prepared via catheters, stents, wires, or other intraluminal devices for delivery. Delivery via such devices may be particularly useful for delivery to the bladder, urethra, ureters, rectum, or intestines.

[0135] Formulations suitable for intravaginal administration include pessaries, tampons, creams, gels, pastes, effervescent agents, or spray formulations containing appropriate carriers known in the art.

[0136] Topical or transdermal dosage forms include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed with a pharmaceutically acceptable carrier under sterile conditions and any preservatives, buffers, or propellants as needed.

[0137] In addition to the active compound, ointments, pastes, creams, and gels may contain excipients such as animal and vegetable fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicic acid, talc, and zinc oxide, or mixtures thereof.

[0138] In addition to the active compound, the powder and spray may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder or mixtures thereof. The spray may further contain conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons such as butane and propane.

[0139] Transdermal patches offer the additional advantage of providing controlled delivery of the compounds of the present invention to the body. Such dosage forms can be formed by dissolving or dispersing the active compound in a suitable medium. Absorption enhancers can also be used to increase the influx of the compound across the skin. The rate of such influx can be controlled by providing a rate-controlled membrane or by dispersing the compound in a polymer matrix or gel.

[0140] Ophthalmic preparations, eye ointments, powders, and solutions are also considered to be within the scope of the present invention. Representative ophthalmic preparations are described in U.S. Patent Publication Nos. 2005 / 0080056, 2005 / 0059744, 2005 / 0031697, and 2005 / 004074, and U.S. Patent No. 6,583,124, the contents of which are incorporated herein by reference. If necessary, the ophthalmic preparations have properties similar to those of tears, aqueous humor, or vitreous humor, or are compatible with such fluids. The preferred route of administration is topical administration (e.g., topical administration such as eye drops or administration via implantation).

[0141] As used herein, the terms "parenteral administration" and "administered parenterally" mean administration other than enteral administration and usually local administration by infusion, and include, but are not limited to, intravenous, intramuscular, intra-arterial, subarachnoid, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, intraspinal, and intrasternal injections and infusions.

[0142] A pharmaceutically acceptable composition suitable for parenteral administration comprises one or more active compounds in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions or sterile powders, which can be reconstituted into a sterile injectable solution or dispersion immediately before use. These may also contain antioxidants, buffers, bacteriostatic agents, solutes or suspensions or thickeners to make the formulation isotonic with the blood of the target recipient.

[0143] Suitable aqueous and non-aqueous carriers that may be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. For example, appropriate fluidity can be maintained by using coating materials such as lecithin, by maintaining the required particle size in the case of dispersants, and by using surfactants.

[0144] These compositions may also contain auxiliary agents such as preservatives, humectants, emulsifiers, and dispersants. The inclusion of various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, and sorbic acid, ensures effective prevention of microbial action. It is also desirable to include isotonic agents such as sugars and sodium chloride in the composition. Furthermore, the inclusion of absorption-delaying agents such as aluminum monostearate and gelatin may lead to prolonged absorption of the injectable pharmaceutical form.

[0145] In some cases, it is desirable to slow down the absorption of a drug from subcutaneous or intramuscular injection in order to prolong its effects. This can be achieved by using a suspension of crystalline or amorphous material with low water solubility. The absorption rate of the drug then depends on its dissolution rate, and in turn, on the crystal size and morphology. Alternatively, the absorption of a parenterally administered drug form can be delayed by dissolving or suspending the drug in an oily vehicle.

[0146] An injectable depot formulation is formed by creating a microencapsulated matrix of this compound on a biodegradable polymer such as polylactic acid-polyglycolide. The rate of drug release can be controlled depending on the ratio of the drug to the polymer and the properties of the specific polymer used. Examples of other biodegradable polymers include poly(orthoester) and poly(anhydride). Injectable formulations of the depot are also prepared by encapsulating the drug in liposomes or microemulsions that are compatible with body tissues.

[0147] For use in the methods of the present invention, the active compound may be provided either by itself or in combination with, for example, a pharmaceutically acceptable carrier, as a pharmaceutical composition containing 0.1 to 99.5% (more preferably 0.5 to 90%) of the active ingredient.

[0148] The delivery method may be provided by a refillable or biodegradable device. Various sustained-release polymer devices have been developed and have recently been tested in vivo for controlling the delivery of drugs, including protein-based biopharmaceuticals. Various biocompatible polymers (including hydrogels), including biodegradable and non-biodegradable polymers, can be used to form implants for sustained release of compounds at specific target sites.

[0149] The actual dose level of the active ingredient in a pharmaceutical composition may be modified to obtain an amount of the active ingredient that is effective in achieving the desired therapeutic response for a particular patient, composition, and mode of administration, provided that it is not toxic to the patient.

[0150] The selected dose level depends on various factors, including those well known in the medical field, such as the activity of the specific compound or the combination of compounds used, or its esters, salts, or amides; the route of administration; the time of administration; the excretion rate of the specific compound(s) used; the continuation of treatment; other drugs, compounds, and / or materials used in combination with the specific compound(s) used; and the age, sex, weight, symptoms, overall health, and medical history of the person being treated.

[0151] A physician or veterinarian with ordinary art in the field can easily determine and prescribe the therapeutically effective dose of the required pharmaceutical composition. For example, a physician or veterinarian can start the dose of the pharmaceutical composition or compound at a level lower than the level required to achieve the desired therapeutic effect and then gradually increase the dose until the desired effect is achieved. By “therapeutably effective dose,” means a concentration of the compound sufficient to produce the desired therapeutic effect. It is generally understood that the effective dose of the compound varies depending on the subject’s weight, sex, age, and medical history. Other factors influencing the effective dose may include, but are not limited to, the severity of the subject’s symptoms, the disorder being treated, the stability of the compound, and, if necessary, other types of therapeutic agents to which the compound of the present invention is administered. A larger total dose may be delivered by multiple administrations of the drug. Methods for determining efficacy and dose are known to those skilled in the art (Isselbacher et al. (1996) Harrison’s Principles of Internal Medicine 13 ed., 1814–1882, which is incorporated herein by reference).

[0152] Generally, the preferred daily dose of the active compound used in the compositions and methods of the present invention is the lowest dose of the compound that is effective in producing a therapeutic effect. Such an effective dose is usually determined by the factors mentioned above.

[0153] If necessary, an effective daily dose of the active compound may be administered in one, two, three, four, five, six or more subdoses, either in unit dosage form, separately at appropriate intervals throughout the day. In certain embodiments of the present invention, the active compound may be administered two or three times daily. In preferred embodiments, the active compound is administered once daily.

[0154] The effective dose of the disclosed compound, when used for the indicated effect, ranges from approximately 0.5 mg to approximately 5000 mg of the disclosed compound necessary to treat the symptoms. Compositions for in vivo or in vitro use may contain approximately 0.5, approximately 5, approximately 20, approximately 50, approximately 75, approximately 100, approximately 150, approximately 250, approximately 500, approximately 750, approximately 1000, approximately 1250, approximately 2500, approximately 3500, or approximately 5000 mg of the disclosed compound, or in a range from some amounts in the dose list to other amounts.

[0155] In certain embodiments, the compounds of the present invention may be used alone or in combination with other types of therapeutic agents. As used herein, “combined administration” means any form of administration of two or more different therapeutic compounds such that the second compound is administered while the previously administered therapeutic compound is still effective in the body (for example, both compounds are effective simultaneously in the subject, and this effectiveness may include a synergistic effect of the two compounds). For example, different therapeutic compounds may be administered simultaneously or sequentially in the same or separate formulations. In certain embodiments, different therapeutic compounds may be administered within 1 hour, 12 hours, 24 hours, 36 hours, 48 ​​hours, 72 hours, or 1 week, respectively. Thus, a subject receiving such treatment may benefit from the combined effects of different therapeutic compounds.

[0156] In certain embodiments, co-administration of the compound of the present invention with one or more additional therapeutic agents enhances the efficacy of the compound of the present invention (e.g., the compound of formula I or Ia) or one or more additional therapeutic agents compared to individual administration. In certain embodiments, co-administration yields an additive effect, where the additive effect represents the sum of the effects of individual administration of the compound of the present invention and one or more additional therapeutic agents.

[0157] The present invention includes the use of pharmaceutically acceptable salts of the compounds of the present invention in compositions and methods of the present invention. In certain embodiments, the possible salts of the present invention include, but are not limited to, alkyl, dialkyl, trialkyl, or tetraalkylammonium salts. In certain embodiments, the possible salts of the present invention include, but are not limited to, L-arginine, bentamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydravamin, 1H-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, 1-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts. In certain embodiments, the possible salts of the present invention include, but are not limited to, Na, Ca, K, Mg, Zn, or other metal salts.

[0158] pharmaceutically acceptable acid addition salts can exist as various solvated compounds, such as water, methanol, ethanol, and dimethylformamide. Mixtures of such solvated compounds can also be prepared. These solvated compounds can be prepared from the crystallization solvent, obtained intrinsically to the crystallization solvent, or obtained incidentally with respect to such a solvent.

[0159] Wetting agents, emulsifiers, lubricants such as sodium lauryl sulfate and magnesium stearate, as well as colorants, release agents, coating agents, sweeteners, flavoring agents and fragrances, preservatives and antioxidants may also be present in the composition.

[0160] Examples of pharmaceutically acceptable antioxidants include (1) water-soluble antioxidants such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, and sodium sulfite; (2) oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, and α-tocopherol; and (3) metal chelating agents such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, and phosphoric acid. [Examples]

[0161] The compound of formula (I) may be prepared by methods known in the field of organic synthesis, partially described by the following synthetic scheme. The compounds described herein may be formed from commercially available starting materials or synthesized using known organic, inorganic and / or enzymatic processes.

[0162] In the scheme described later, the use of protecting groups for sensitive or reactive groups is well known, where necessary according to general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (TW Greene and PGMWuts, "Protective Groups in Organic Synthesis, Third edition, Wiley, New York 1999). These groups are removed using methods readily apparent to those skilled in the art at a convenient stage in the compound synthesis. The selection process, as well as the reaction conditions and the order in which they are carried out, should be consistent with the preparation of the compound of formula (I).

[0163] Those skilled in the art will recognize that the stereocenter is located in the compound of formula (I). Therefore, this disclosure includes both possible stereoisomers (if not specified in the synthesis) and includes not only racemic compounds but also individual enantiomers and / or diastereomers. Where the compound is desired as a single enantiomer or diastereomer, it can be obtained by stereospecific synthesis or by the separation of the final product or any convenient intermediate. The separation of the final product, intermediate, or starting material may also be influenced by any publicly known methods in the art. See, for example, “Stereochemistry of Organic Compounds” by ELEliel, S. Wilen, and LNMander (Wiley-Interscience, 1994). Enantiomers, diastereomers, and mixtures of cis / trans isomers obtained from the above processes can be separated into these single components by chiral salt techniques, normal-phase, reverse-phase, or chiral column chromatography, depending on the nature of the separation.

[0164] This disclosure is further illustrated by the following examples and synthesis schemes, which are not intended to limit the scope or spirit of this disclosure to the specific procedures described herein. It should be understood that these examples are provided to illustrate specific embodiments and are not intended to limit the scope of the disclosure. It should be further understood that various other embodiments, variations and equivalents themselves are suggested to those skilled in the art, without departing from the spirit and / or the appended claims.

[0165] Analytical methods, materials and measurements Unless otherwise specified, reagents and solvents were used as they were obtained from commercial suppliers. All commercially available starting materials were purchased from Sigma Aldrich, Fisher Scientific, Oakwood Chemical, and Combi Block. All reagents were used as obtained without further purification. Known compounds were synthesized according to the procedures in the cited literature, and any variants are described. Anhydrous solvents such as tetrahydrofuran (THF), diethyl ether, dichloromethane (DCM), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,4-dioxane, and toluene (PhMe) were purchased from Fisher Scientific and used as obtained. Where necessary, air or moisture-sensitive reactions were carried out under an inert nitrogen atmosphere.

[0166] The solvent was removed using a Buchi R-300 rotary evaporator, followed by further concentration using a Welch 1400B-01 vacuum line and a Labconco FreeZone 6 plus system. The compound was purified by normal-phase column chromatography using a Teledyne CombiFlash chromatography system and / or reverse-phase chromatography using a SunFire® Prep C18 OBD™ 5μM column in a Waters Micromass ZQ preparation system. Purity was analyzed using a Waters Acquity UPLC system. Analytical thin-layer chromatography (TLC) plates were purchased from Fisher Scientific (EMD Millipore TLC Silica Gel60 F254). Visualization was achieved by irradiation under ultraviolet light (254 nm).

[0167] All ¹H-NMR spectra were recorded at 298K using a Bruker ARX 500 (500MHz) spectrometer. ¹³C-NMR spectra were recorded using a Bruker ARX 500 (126MHz) spectrometer. Samples were dissolved in CDCl3, DMSO-d6, or CD3OD. Spectra were referenced to residual solvent peaks (chloroform-d: 7.26 ppm for ¹H-NMR and 77.16 ppm for ¹³C-NMR; DMSO-d6: 2.50 ppm for ¹H-NMR and 39.25 ppm for ¹³C-NMR; CD3OD: 3.31 ppm for ¹H-NMR and 49.00 ppm for ¹³C-NMR, or trimethylsilane (TMS) as an internal standard). Chemical shift, multiplicity (s=single line, d=double line, t=triple line, q=quadruple line, m=multiple line, br=broad peak), and proton number. Mass spectrometry (LCMS) data were obtained using a Waters Acquity UPLC system in positive ESI mode.

[0168] Example 1: Representative synthesis of the compounds of this disclosure [ka] S1.R=Cl; S2.R=NO2 2-aminobenzoic acid (10.0 mmol) and formaldehyde (1.8 g, 40.0 mmol) were mixed in a pressure tube and heated overnight at 150°C. The reaction was then cooled to room temperature. The solid was suspended in cold water, recovered by vacuum filtration, and dried in a high vacuum line. Without further purification, 1.6 g (-Cl) and 1.8 g (-NO2) of the product were isolated as a slightly brown solid in yields of 88% (-Cl) and 95% (-NO2), respectively.

[0169] [ka] Sodium hydride (60% dispersion in mineral oil) (0.88 g, 22.0 mmol) was dissolved in 40 mL of anhydrous DMSO at 0°C under N2. Trimethylsulfoxonium iodide (4.84 g, 22.0 mmol) was gradually added to the solution. Once the addition was complete, the mixture was warmed to room temperature and stirred for 40 minutes. Then, 1-Boc-4-piperidone (3.98 g, 20.0 mmol) was gradually added. Next, the reaction mixture was stirred at room temperature for 1 hour, and then stirred at 65°C for another hour. The mixture was poured onto 100 mL of ice. The aqueous phase was extracted using siRNA (50 mL x 2). The combined organic phase was washed with brine, dried over MgSO4, filtered, and evaporated under reduced pressure. The crude material was purified by flash column chromatography (50% siRNA in hexane) to obtain 2.98 g of product in 70% yield.

[0170] [ka] S4.R=Cl; S5.R=NO2 To an aqueous solution of S1 (2.13 g, 11.8 mmol) in 50 mL of DMF, S3 (2.78 g, 13.0 mmol) and Cs2CO3 (11.54 g, 35.4 mmol) were added. The mixture was heated overnight at 80°C. The reaction was then cooled to room temperature and diluted with phenylethylamine. The solution was washed with saturated NH4Cl (50 mL x 2), and the aqueous phase was extracted with another phenylethylamine. The combined organic phase was washed with brine, dried over MgSO4, filtered, and evaporated under reduced pressure. The crude material was purified by flash column chromatography (40% to 100% phenylethylamine in hexane) to obtain 3.94 g of product in 85% yield.

[0171] [ka] S4.R=Cl;S5.R=NO2;S6.R=Cl;S7.R=NO2 S4 was taken as a 1M solution in trifluoroacetic acid (TFA) and stirred at room temperature for 2 hours. The solution was concentrated under reduced pressure and then under high vacuum overnight. Without further purification, S6 was used as the starting material for the following synthesis.

[0172] [ka] S6.R=Cl; S7.R=NO2 Amide formation by HATU catalytic coupling reaction S6 was taken as a 1M solution in DMF, and 3 equivalents of Et3N were added. HATU (2 eq), Et3N (5 eq), and carboxylate (1.2 eq) were pre-mixed in DMF at the same concentration and stirred at room temperature for 10 minutes. Next, the two solutions were mixed and stirred further at room temperature for 5 hours. The reaction was directly purified by preparative HPLC. The isolated product was then further purified by normal-phase flash chromatography to obtain a product with the desired purity for the following biological tests.

[0173] [ka] Amide formation by acylation using acid chlorides S6 (0.04 g, 0.1 mmol) was added to 2 mL of dichloromethane. Et3N (0.07 mL, 0.5 mmol) was added, followed by acetyl chloride (0.015 mL, 0.2 mL). The mixture was stirred for 2 hours and the reaction was stored at 0°C. The reaction was then stopped by adding water dropwise, and immediate purification was performed by flash column chromatography. Product 6 isolated by HPLC was further purified to obtain 19 mg of product in 57% yield.

[0174] [ka] Reduction of aromatic nitro groups S7 (0.49 g, 1.08 mmol) was dissolved in 10 mL of AcOH / EtOH (1:1). Iron powder (0.25 g, 4.39 mmol) was added all at once. The reaction was then stirred at 50°C for 1 hour. The iron powder was removed by filtration. The filtrate was concentrated under reduced pressure. The crude material was purified by normal-phase flash column chromatography (10%-40% MeOH in HCl), and after reverse-phase HPLC, 0.22 g of product S8 was obtained in 53% yield.

[0175] [ka] Introduction of soluble groups S8 (0.11 g, 0.25 mmol) was dissolved in 5 mL of dichloromethane. Et3N (0.035 mL, 0.25 mmol) was added at -20°C. 3-bromopropionyl chloride (0.03 mL, 0.25 mmol) in 1 mL of DCM was added dropwise. The reaction was stirred at 0°C for 3 hours. Then, water was added dropwise to stop the reaction, and the mixture was concentrated under reduced pressure. The crude product was used in the next step without further purification.

[0176] Crude material (0.06 g, 0.1 mmol) from the final step was dissolved in 1 mL of DMF. N-methylpiperazine (0.016 mL, 0.12 mmol) and Et3N (0.028 mL, 0.2 mmol) were added to the solution. The reaction was stirred at 80°C for 3 hours. The solution was directly purified by reverse-phase HPLC, followed by normal-phase flash column chromatography (20%-60% MeOH in HCl with 0.5% Et3N) to obtain 0.043 g of product 10 in 75% yield. The following compounds were synthesized using these procedures and their variations.

[0177] [ka] 1 ((R)-7-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidine-4-yl)methyl)quinazoline-4(3H)-one: white solid, yield 50%) 1H NMR (500 MHz, DMSO) δ 8.27 (d, J = 12.8 Hz, 1H), 8.16 (d, J = 8.6 Hz, 1H), 7.75 (d, J = 1.7 Hz, 1H), 7.58 (dd, J = 8.6, 2.0 Hz, 1H), 7.26 (dd, J = 13.8, 6.7 Hz, 4H), 7.20-7.08 (m, 1H), 4.93 (d, J = 5.9 Hz, 1H), 4.04 (d, J = 13.6 Hz, 2H), 3.92 (q, J = 13.9 Hz, 1H), 3.65 (t, J = 12.5 Hz, 1H), 3.28-3.06 (m, 2H), 2.86 (ddd, J = 13.9, 8.6, 3.2 Hz, 1H), 2.68-2.50 (m, 2H), 1.62-1.26 (m, 3H), 1.26-1.12 (m, 3H). 13 C NMR (126 MHz, DMSO) δ 168.92, 159.90, 150.16, 148.76, 146.43, 146.31, 138.70, 128.22, 127.99, 127.96, 126.98, 126.68, 126.64, 125.99, 125.74, 125.69, 120.12, 69.05, 69.00, 53.58, 40.82, 40.71, 39.99, 36.68, 36.01, 35.78, 34.78, 34.65, 34.09, 33.95, 21.83, 21.63.LCMS (ESI) m / z 440.29 [(M+H) + ;C 24 H 27 ClN3O3 + Calculated value for: 440.17].

[0178] [ka] 2 (7-Chloro-3-((1-(3-phenylpropanoyl)piperidine-4-yl)methyl)quinazoline-4(3H)-one: white solid, yield 33%) 11H NMR (500 MHz, CDCl3) δ 8.21 (d, J = 8.6 Hz, 1H), 7.93 (s, 1H), 7.70 (d, J = 1.9 Hz, 1H), 7.46 (dd, J = 8.6, 2.0 Hz, 1H), 7.31 - 7.25 (m, 2H), 7.22 - 7.18 (m, 3H), 4.69 (d, J = 13.4 Hz, 1H), 3.88 - 3.73 (m, 3H), 3.00 - 2.92 (m, 2H), 2.91 - 2.82 (m, 1H), 2.60 (dp, J = 14.3, 7.3 Hz, 2H), 2.48 (td, J = 13.1, 2.4 Hz, 1H), 2.17 - 2.04 (m, 1H), 1.70 (d, J = 12.9 Hz, 1H), 1.62 (d, J = 12.8 Hz, 1H), 1.17 (qd, J = 12.5, 4.3 Hz, 1H), 0.97 (qd, J = 12.5, 4.2 Hz, 1H). 13 13C NMR (126 MHz, DMSO) δ 169.56, 159.76, 149.58, 148.95, 141.43, 138.88, 128.37, 128.18, 127.28, 126.30, 125.79, 120.37, 50.79, 44.55, 40.74, 38.22, 35.01, 33.98, 30.87, 29.54, 28.84. LCMS (ESI) m / z 410.29 [(M + H) + ; C 23 H 25 ClN3O2 + calculated for: 410.16].

[0179]

Chemical Structure

[0180] [ka] 4 (7-Chloro-3-((4-Hydroxy-1-(3-phenylpropyl)piperidine-4-yl)methyl)quinazoline-4(3H)-one: White solid, yield 13%) 1 1H NMR (500 MHz, MeOD) δ 8.29 (s, 1H), 8.21 (d, J = 8.6 Hz, 1H), 7.69 (d, J = 1.9 Hz, 1H), 7.54 (dd, J = 8.6, 2.0 Hz, 1H), 7.26 (q, J = 7.1 Hz, 2H), 7.21-7.13 (m, 3H), 4.11 (s, 2H), 2.97 (d, J = 12.0 Hz, 2H), 2.76-2.59 (m, 6H), 1.98-1.81 (m, 4H), 1.63 (d, J = 13.4 Hz, 2H). 13 C NMR (126 MHz, MeOD) δ 161.13, 149.97, 148.77, 140.38, 140.25, 128.24, 128.13, 128.00, 127.52, 126.00, 120.22, 67.60, 56.16, 53.81, 48.21, 32.27, 32.00, 25.90.LCMS (ESI) m / z 412.39 [(M+H) + ;C 23 H 27 ClN3O2 + Calculated value for: 412.18].

[0181] [ka] 5 (7-Chloro-3-((3-hydroxy-1-(3-phenylpropanoyl)pyrrolidine-3-yl)methyl)quinazoline-4(3H)-one: white solid, yield 8%) 1 H NMR (500 MHz, DMSO) δ 8.29 (s, 1H), 8.17 (dd, J = 8.6, 4.3 Hz, 1H), 7.76 (t, J = 2.3 Hz, 1H), 7.59 (ddd, J = 8.7, 7.5, 2.1 Hz, 1H), 7.29-7.19 (m, 4H), 7.16 (t, J = 6.8 Hz, 1H), 5.27 (s, 1H), 4.17 (s, 1H), 4.14 (d, J = 4.0 Hz, 1H), 3.51 (s, 2H), 3.32 (dt, J = 23.6, 11.7 Hz, 3H), 2.84-2.74 (m, 2H), 2.59-2.51 (m, 2H), 2.47-2.40 (m, 1H), 1.95 (ddt, J = 39.5, 12.7, 9.3 Hz, 1H), 1.76 (ddd, J = 12.9, 11.0, 5.7 Hz, 1H). 13 C NMR (126 MHz, DMSO) δ 169.93, 169.76, 160.22, 160.13, 150.33, 149.06, 149.04, 141.55, 141.51, 138.95, 128.45, 128.40, 128.35, 128.22, 127.24, 126.27, 125.81, 120.46, 78.33, 76.84, 55.97, 55.57, 51.10, 50.87, 44.46, 43.77, 36.06, 35.63, 35.06, 34.54, 30.29, 30.23.LCMS (ESI) m / z 412.29 [(M+H) + ;C 22 H 23 ClN3O3 + Calculated value for: 412.14].

[0182] [ka] 6 (3-((1-acetyl-4-hydroxypiperidine-4-yl)-7-chloroquinazoline-4(3H)-one: white solid, yield 57%) 1H NMR (500 MHz, DMSO) δ 8.40 (s, 1H), 8.15 (d, J = 8.6 Hz, 1H), 7.75 (d, J = 2.0 Hz, 1H), 7.57 (dd, J = 8.6, 2.1 Hz, 1H), 4.09-3.96 (m, 4H), 3.58 (d, J = 13.4 Hz, 1H), 3.33-3.20 (m, 1H), 2.97-2.85 (m, 1H), 1.98 (s, 3H), 1.56 (td, J = 13.3, 4.3 Hz, 1H), 1.49-1.34 (m, 3H). 13 C NMR (126 MHz, DMSO) δ 167.66, 159.89, 150.25, 148.62, 138.65, 128.19, 126.92, 125.88, 120.05, 68.98, 53.39, 41.40, 36.44, 34.61, 33.93, 20.98.LCMS (ESI) m / z 336.18 [(M+H) + ;C 16 H 19 ClN3O3 + Calculated value for: 336.11].

[0183] [ka] 7 (7-Chloro-3-((4-hydroxy-1-(2-phenylacetyl)piperidine-4-yl)methyl)quinazoline-4(3H)-one: white solid, commercially available compound) 1 1H NMR (500 MHz, DMSO) δ 8.27 (s, 1H), 8.15 (d, J = 8.6 Hz, 1H), 7.75 (d, J = 2.0 Hz, 1H), 7.57 (dd, J = 8.6, 2.1 Hz, 1H), 7.30-7.24 (m, 2H), 7.24-7.15 (m, 3H), 4.07-4.03 (m, 1H), 3.97 (dd, J = 38.6, 13.8 Hz, 2H), 3.74-3.64 (m, 3H), 3.29-3.20 (m, 1H), 3.03-2.92 (m, 1H), 1.51-1.27 (m, 4H). 13 C NMR (126 MHz, DMSO) δ 168.31, 159.88, 150.12, 148.71, 138.66, 135.76, 128.57, 128.19, 127.99, 126.93, 126.00, 125.95, 120.07, 68.97, 53.45, 41.15, 39.35, 36.86, 34.61, 33.99.LCMS (ESI) m / z 412.29 [(M+H) + ;C 22 H 23 ClN3O3 + Calculated value for: 412.14].

[0184] [ka] 8 (7-Chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidine-4-yl)methyl)quinazoline-4(3H)-one: white solid, commercially available compound) 1 H NMR (500 MHz, DMSO) δ 8.29 (s, 1H), 8.18 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 2.0 Hz, 1H), 7.56 (dd, J = 8.6, 2.1 Hz, 1H), 7.30-7.22 (m, 4H), 7.18-7.13 (m, 1H), 4.12-3.55 (m, 4H), 3.41-2.85 (m, 3H), 2.62 (dd, J = 14.9, 6.6 Hz, 1H), 2.54 (dd, J = 14.9, 7.6 Hz, 1H), 1.40 (t, J = 15.9 Hz, 4H), 1.25 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 168.89, 159.94, 159.88, 150.11, 148.74, 146.42, 146.30, 138.68, 128.20, 127.97, 127.94, 126.94, 126.66, 126.63, 125.98, 125.72, 125.67, 120.10, 69.04, 68.99, 53.57, 40.82, 40.71, 39.99, 36.67, 35.99, 35.77, 34.78, 34.64, 34.09, 33.95, 21.81, 21.61.LCMS (ESI) m / z 440.39 [(M+H) + ; C 24 H 27 ClN3O3 + Calculated value for: 440.17].

[0185] [ka] 9 ((S)-7-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)pipericin-4-yl)methyl)quinazoline-4(3H)-one: white solid, yield 57%) 11H NMR (500 MHz, DMSO) δ 8.27 (d, J = 12.8 Hz, 1H), 8.16 (d, J = 8.6 Hz, 1H), 7.75 (d, J = 1.6 Hz, 1H), 7.58 (dd, J = 8.6, 2.0 Hz, 1H), 7.26 (dd, J = 13.7, 6.6 Hz, 4H), 7.21 - 7.09 (m, 1H), 4.93 (d, J = 5.8 Hz, 1H), 3.99 (dd, J = 43.9, 13.7 Hz, 2H), 3.91 (s, 1H), 3.65 (t, J = 12.2 Hz, 1H), 3.28 - 3.09 (m, 2H), 2.85 (d, J = 13.2 Hz, 1H), 2.68 - 2.55 (m, 2H), 1.60 - 1.25 (m, 3H), 1.20 (dd, J = 6.9, 1.5 Hz, 3H). 13 13C NMR (126 MHz, DMSO) δ 168.89, 159.94, 159.88, 150.11, 148.74, 146.42, 146.30, 138.68, 128.20, 127.97, 127.94, 126.94, 126.66, 126.63, 125.98, 125.72, 125.67, 120.10, 69.04, 68.99, 53.57, 40.82, 40.71, 39.99, 36.67, 35.99, 35.77, 34.78, 34.64, 34.09, 33.95, 21.81, 21.61. LCMS (ESI) m / z 440.29 [(M + H) + ; C 24 H 27 ClN3O3 + Calculated for: 440.17].

[0186]

Chemical Structure

[0187] [ka] 11 ((S)-N-(3-((4-hydroxy-1-(3-phenylbutanoyl)piperidine-4-yl)methyl)-4-oxo-3,4-dihydroquinazoline-7-yl)-3-(4-methylpiperazine-1-yl)propanamide: Off-white solid, yield 26%) 1 H NMR (500 MHz, DMSO) δ 10.52 (s, 1H), 8.19 (d, J = 13.1 Hz, 1H), 8.08 (d, J = 8.7 Hz, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.62 (dd, J = 8.8, 1.4 Hz, 1H), 7.25 (dd, J = 12.6, 6.3 Hz, 4H), 7.19-7.08 (m, 1H), 4.93 (s, 1H), 4.08-3.97 (m, 1H), 3.90 (q, J = 14.0 Hz, 2H), 3.64 (t, J = 12.9Hz, 1H), 3.30-3.09 (m, 2H), 2.95-2.81 (m, 1H), 2.69-2.60 (m, 2H), 2.61-2.52 (m, 3H), 2.47-2.25 (m, 8H), 2.15 (s, 3H), 1.58-1.26 (m, 4H), 1.24-1.14 (m, 3H). 13C NMR (126 MHz, DMSO) δ 170.76, 168.82, 159.88, 149.11, 148.74, 146.41, 146.29, 144.04, 127.94, 127.91, 127.00, 126.63, 125.69, 125.64, 118.04, 116.28, 114.46, 68.99, 54.43, 53.24, 52.02, 45.38, 40.82, 40.71, 39.96, 36.68, 35.96, 35.75, 34.77, 34.64, 34.03, 21.80, 21.61.LCMS (ESI) m / z 575.32 [(M+H) + ;C 32 H 43 ClN6O4 + Calculated value for: 575.33].

[0188] [ka] 12 (N-(3-((4-hydroxy-1-(3-phenylbutanoyl)piperidine-4-yl)methyl)-4-oxo-3,4-dihydroquinazoline-7-yl)-3-(4-methylpiperazine-1-yl)propenamide: white solid, yield 16%) 1 H NMR (500 MHz, DMSO) δ 10.84 (s, 1H), 8.25 (d, J = 13.2 Hz, 1H), 8.15-7.99 (m, 2H), 7.69 (d, J = 8.7 Hz, 1H), 7.28-7.25 (m, 4H), 7.19-7.10 (m, 1H), 4.05-3.88 (m, 3H), 3.65 (t, J = 12.8 Hz, 1H), 3.28-3.14 (m, 10H), 2.92-2,85 (m, 3H), 2.79 (s, 3H), 2.64-2.53 (m, 4H), 1.53-1.28 (m, 4H), 1.20 (d, J = 6.0, 3H). 13C NMR (126 MHz, DMSO) δ 169.60, 160.66, 160.61, 158.82, 158.57, 149.95, 149.34, 147.15, 147.02, 144.63, 128.69, 128.66, 127.69, 127.38, 127.35, 126.44, 126.39, 118.90, 117.14, 115.37, 69.76, 69.71, 53.94, 41.57, 41.46, 40.88, 40.70, 37.42, 36.71, 36.49, 35.50, 35.37, 34.81, 34.66, 22.53, 22.34.LCMS (ESI) m / z 575.32 [(M+H) + ;C 32 H 43 ClN6O4 + Calculated value for: 575.33].

[0189] [ka] 13 (N-(3-((4-hydroxy-1-(4-methyl-3-phenylpentanoyl)piperidine-4-yl)methyl)-4-oxo-3,4-dihydroquinazoline-7-yl)-3-(4-methylpiperazine-1-yl)propenamide: off-white solid, yield 40%) 1 H NMR (500 MHz, DMSO) δ 10.65 (s, 1H), 8.21 (d, J = 16.9 Hz, 1H), 8.11 (dd, J = 8.7, 1.9 Hz, 1H), 8.05 (s, 1H), 7.65 (d, J = 8.7 Hz, 1H), 7.23 (td, J = 7.6, 2.9 Hz, 2H), 7.15 (t, J = 6.5 Hz, 2H), 7.13-7.06 (m, 1H), 4.04-3.93 (m, 2H), 3.85 (s, 1H), 3.75-3.61 (m, 1H), 3.58-2.98 (m, 10H), 2.91-2.55 (m, 10H), 1.88-1.80 (m, 1H), 1.53-1.25 (m, 3H), 1.12-1.06 (m, 1H), 0.89 (t, J = 7.2 Hz, 3H), 0.70-0.61 (m, 3H). 13 C NMR (126 MHz, DMSO) δ 169.94, 169.86, 160.61, 160.53, 149.95, 149.29, 144.51, 144.09, 144.03, 128.82, 128.79, 128.24, 128.16, 127.81, 126.31, 118.89, 117.21, 115.33, 69.76, 69.66, 54.04, 50.83, 49.24, 49.08, 48.75, 42.48, 41.51, 37.43, 37.33, 36.01, 35.94, 35.55, 35.31, 34.72, 34.65, 32.83, 32.63, 32.39, 21.24, 21.19, 20.76, 20.56.LCMS (ESI) m / z 603.43 [(M+H) + ;C 34 H 47 ClN6O4 + Calculated value for: 603.37].

[0190] [ka] 14((R)-N-(3-((4-hydroxy-1-(3-phenylbutanoyl)piperidine-4-yl)methyl)-4-oxo-3,4-dihydroquinazoline-7-yl)-3-morpholinopropanamide: Off-white solid, yield 65%) 11H NMR (500 MHz, DMSO) δ 10.52 (s, 1H), 8.20 (d, J = 13.3 Hz, 1H), 8.07 (d, J = 8.7 Hz, 1H), 8.04 (d, J = 1.8 Hz, 1H), 4.96 (d, J = 6.4 Hz, 1H), 4.02 (d, J = 13.7 Hz, 1H), 3.90 (q, J = 14.0 Hz, 2H), 3.73 - 3.60 (m, 1H), 3.59 - 3.55 (m, 4H), 3.18 (ddd, J = 21.0, 18.3, 9.2 Hz, 2H), 2.93 -  2.80 (m, 1H), 2.65 (t, J = 6.9 Hz, 2H), 2.61 - 2.54 (m, 3H), 2.41 (m, 4H), 1.40 (dddd, J = 41.2, 26.0, 16.8, 9.5 Hz, 4H), 1.19 (dd, J = 6.9, 1.7 Hz, 3H). 13 13C NMR (126 MHz, DMSO) δ 170.62, 168.81, 160.00, 149.15, 148.76, 146.44, 146.31, 144.09, 118.13, 116.29, 114.51, 69.06, 65.93, 53.73, 52.79, 40.85, 40.75, 39.98, 36.71, 36.00, 35.78, 34.79, 34.66, 34.11, 33.98, 33.81, 21.83, 21.64. LCMS (ESI) m / z 562.32 [(M+H) + ; C 31 H 40 ClN5O5 + calculated for: 562.30]. <00014​​​​​​​​((R)-3-(dimethylamino)-N-(3-((4-hydroxy-1-(3-phenylbutanoyl)piperidine-4-yl)methyl)-4-oxo-3,4-dihydroquinazoline-7-yl)propanamide: off-white solid, yield 36%) 1 H NMR (500 MHz, DMSO) δ 10.47 (s, 1H), 8.18 (dd, J = 13.0, 7.3 Hz, 1H), 8.06 (d, J = 8.7 Hz, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.63-7.59 (m, 1H), 7.24 (dd, J = 12.6, 6.3 Hz, 4H), 7.17-7.09 (m, 1H), 4.92 (s, 1H), 4.07-3.95 (m, 1H), 3.89 (q, J = 14.0 Hz, 2H), 3.63 (t, J = 13.0 Hz, 1H), 3.18 (ddd, J = 20.8, 18.0, 9.1 Hz, 2H), 2.86 (ddd, J = 13.8, 10.5, 5.5 Hz, 1H), 2.60-2.54 (m, 3H), 2.54-2.47 (m, 2H), 2.17 (s, 6H), 1.56-1.23 (m, 4H), 1.24-1.15 (m, 3H). 13 C NMR (126 MHz, DMSO) δ 170.76, 168.83, 159.89, 149.09, 148.74, 146.42, 146.29, 144.07, 127.94, 127.92, 126.97, 126.61, 125.70, 125.64, 118.06, 116.26, 114.46, 68.99, 54.59, 53.29, 44.63, 40.82, 40.72, 39.98, 39.96, 36.68, 35.97, 35.75, 34.78, 34.65, 34.61, 34.11, 33.96, 21.80, 21.61.LCMS (ESI) m / z 520.31 [(M+H) + ;C 29 H 38 ClN5O4+ Calculated value for: 520.29].

[0192] [ka] 16 (N-(3-((4-hydroxy-1-(3-phenylbutanoyl)piperidine-4-yl)methyl)-4-oxo-3,4-dihydroquinazoline-7-yl)-3-(1H-imidazole-1-yl)propenamide: white solid, yield 19%) 1 H NMR (500 MHz, DMSO) δ 10.62 (s, 1H), 9.16 (s, 1H), 8.22 (d, J = 12.9 Hz, 1H), 8.09 (d, J = 8.7 Hz, 1H), 8.00 (s, 1H), 7.80 (s, 1H), 7.67 (s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 7.28-7.25 (m, ,4H), 7.15 (d, J = 3.6 Hz, 1H), 4.03-3.87 (m, 3H), 3.65 (t, J = 12.4 Hz, 1H), 3.26-3.14 (m, 2H), 3.08 (t, J = 6.3 Hz, 2H), 2.90-2.85 (m, 1H), 2.64-2.49 (m, 4H), 1.54-1.25 (m, 4H), 1.20 (d, J = 5.4 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 169.60, 169.43, 160.60, 160.55, 158.88, 158.60, 149.99, 149.25, 147.15, 147.03, 144.33, 136.33, 128.68, 128.66, 127.85, 127.37, 127.35, 126.44, 126.39, 122.58, 120.32, 118.86, 117.25, 115.33, 69.77, 69.71, 54.04, 44.94, 41.55, 41.44, 40.71, 37.41, 36.70, 36.57, 36.49, 35.52, 35.39, 34.80, 34.66, 22.53, 22.35.LCMS (ESI) m / z 543.22 [(M+H) + ;C 30 H 35 ClN6O4 + Calculated value for: 543.27].

[0193] [ka] 17 ((N-(3-((4-hydroxy-1-(3-phenylbutanoyl)piperidine-4-yl)methyl)-4-oxo-3,4-dihydroquinazoline-7-yl)-3-(piperidine-1-yl)propenamide: white solid, yield 18%) 1 H NMR (500 MHz, DMSO) δ 10.69 (s, 1H), 9.32 (s, 1H), 8.23 (d, J = 12.8 Hz, 1H), 8.11 (dd, J = 8.7, 1.9 Hz, 1H), 8.05 (s, 1H), 7.65 (d, J = 8.7 Hz, 1H), 7.19-7.31 (m, 4H), 7.15 (s, 1H), 4.03-3.89 (m, 3H), 3.65 (t, J = 12.4 Hz, 1H), 3.48-3.40 (m, 4H), 3.26-3.15 (m, 2H), 2.98-2.89 (m, 5H), 2.64-2.51 (m, 2H), 1.84 (d, J = 13.3 Hz, 2H), 1.68-1.62 (m, 3H), 1.55-1.31 (m, 5H), 1.21 (d, J = 6.6 Hz, 3H). 13 C NMR (126 MHz, DMSO) δ 169.60, 169.22, 160.61, 160.56, 158.87, 158.59, 150.01, 149.29, 147.15, 147.03, 144.41, 128.68, 128.66, 127.87, 127.37, 127.35, 126.44, 126.39, 118.89, 117.27, 115.38, 69.77, 69.72, 54.05, 52.89, 52.05, 41.55, 41.45, 40.69, 37.41, 36.71, 36.49, 35.53, 35.40, 34.81, 34.67, 31.22, 23.00, 22.53, 22.35, 21.65.LCMS (ESI) m / z 560.22 [(M+H) + ;C 32 H 42 ClN5O4 + Calculated value for: 560.32].

[0194] Example 3: Bioassay USP7 enzyme expression and purification The structure of human USP7 encompassing residues 208–560 of the pET28aLIC vector was overexpressed in terrific broth (TB) medium on E. coli BL21 (DE3) in the presence of 50 μg / mL kanamycin. Cells were grown at 37°C until OD0.8, cooled to 17°C, and induced with 500 μM isopropyl alcohol-1-thio-D-galactopyranoside (IPTG). The cells were incubated overnight at 17°C, harvested by centrifugation, and stored at -80°C. The cell pellet was sonicated in buffer A (50 mM HEPES pH 7.5, 300 mM NaCl, 10% glycerol, 10 mM imidazole, and 3 mM BME), and the resulting lysate was centrifuged at 30,000 xg for 40 minutes. Ni-NITA beads (Qiagen) were mixed with the supernatant of the lysate for 30 minutes, and the cells were washed with buffer A. The beads were transferred to an FPLC-compatible column, and the bound protein was washed with 15% Buffer B (50 mM HEPES pH 7.5, 300 mM NaCl, 10% glycerol, 300 mM imidazole, and 3 mM BME), and eluted with 100% Buffer B. Thrombin was added to the eluted protein and incubated overnight at 4°C. The sample was concentrated and passed through a Superdex200 16 / 60 column (GE Healthcare) in a buffer containing 20 mM HEPES pH 7.5, 200 mM NaCl, 5% glycerol, and 1 mM TCEP. The fractions were pooled, concentrated, and frozen at -80°C.

[0195] Full-length USP7 (aa 0001.1102) in pET28aLIC was transformed into BL21(DE3) cells. Using an overnight culture, 1 L of TB supplemented with 50 μg / mL chaomycin was seeded. Cells were grown at 37°C until they reached an optical density (OD) of approximately 0.6 at 600 nm. Protein expression was initiated by the addition of 0.4 mM IPTG. Cells were then grown at 17°C for 16–20 hours before harvesting by centrifugation. The cell pellet was washed in PBS, resuspended in 25 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 1 mM TCEP, 10 mM imidazole, and 0.1% IGEPAL, sonicated, and incubated with Ni-Nta beads (Quiagen) for 30 minutes at 4°C. The beads were washed with 10% buffer B (25 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 1 mM TCEP, 250 mM imidazole) and eluted with 100% buffer B. The proteins containing the fractions were concentrated and packed into a Superdex200 10 / 300GL column in a buffer containing 20 mM HEPES pH 7.5, 200 mM NaCl, 5% glycerol, and 1 mM TCEP. The fractions were pooled, concentrated, and frozen at -80°C.

[0196] Site-directed mutagenesis Amino acid mutations in the catalytic domain and full-length USP7 were introduced by PCR using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's protocol. Table 1 lists the primers used for each mutation created. [Table 1-1] [Table 1-2]

[0197] Isothermal titration calorimetry Protein / ligand binding affinity was measured by adding 0.02 mM protein to cells and titrating with 0.2 mM ligand in a syringe using an Auto-ITC200 microcalorimeter (Malvern) at 20°C (Figure 2C). Proteins and ligands were prepared in ITC buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl, and 2% DMSO. Data were fitted using Origin 7.0 software. The ITC results are summarized in Table 2. [Table 2]

[0198] Selective profiling Selective profiling (DUBProfiler) was performed using Ubiquigent with the manufacturer's protocol. Figure 2B shows dose-dependent inhibition of the USP7 catalytic domain by compounds A, 10, and 11. Figure 2D shows the inhibitory activity of compound 10 across a panel of 41 purified DUBs using ubiquitin-rhodamine (Ub-Rho) as the substrate.

[0199] Antagonistic activity-based protein profiling HEK293T cells were pelleted, washed with PBS, lysed on ice, and treated with a phosphatase inhibitor cocktail (Sigma P5726 and Calbiochem 524624) and protease inhibitors (pepstatin, leupeptin, PMSF, and aprotinin) in 50 mM Tris pH 7.6, 150 mM NaCl, 5 mM MgCl2, 0.5 mM EDTA, 0.5% NP-40, 10% glycerol, 1 mM TCEP). Impurities were removed by centrifugation. Protein content was quantified by BCA, and 50 μg of lysate was diluted in 30 μL of labeled buffer (50 mM Tris pH 7.6, 5 mM MgCl2, 0.5 mM EDTA, 250 mM sucrose, 1 mM TCEP) and incubated at room temperature for 30 minutes with shaking of the indicated inhibitor. The sample was then treated with 1 mM The sample was supplemented with HA-Ub-Bs and incubated at room temperature for 15 minutes with shaking. The reaction was stopped with 4x LDS sample buffer (Thermo Fisher B0007) supplemented with 10% BME, vortexed vigorously, and heated to 95°C for 5 minutes. The sample was degraded by SDS-PAGE and analyzed by Western blotting using the indicated antibody (Figure 5C).

[0200] Cell processing MCF7 and MM.1S cells were grown in RPMI supplemented with 10% fetal bovine serum (FBS) and antibiotics. Cells were treated with DMSO or compounds 10 and 11 at various concentrations for 6 hours (MM1S) or 16 hours (MCF7) in or without cycloheximide. For experiments in which cycloheximide was used, cells were treated with the compound for 4 hours (MM1S) or 14 hours (MCF7) before the addition of 50 ug / mL of cycloheximide. Cells were washed with PBS at 6 or 16 hours and denatured RIPA buffer containing phosphatase inhibitor cocktails 1 and 2 (Sigma) and protease inhibitors (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 20 mM). The protein was dissolved in Tris, 150 mM NaCl, and 1 mM EDTA. The protein concentration was quantified using the BCA protein analysis kit (Pierce), and mdm2 (santa The samples were identified by immunoblotting using the following antibodies: cruz sc-965, p53 (cell signaling 9282), p21 (cell signaling 2947), GAPDH (cell signaling 2118), and USP7 (cell signaling 4833) (Figures 6A-D).

[0201] Peripheral blood mononuclear cell test Peripheral blood mononuclear cells (PBMCs) were generously provided by Dr. Steven Treon and Dr. Guang Yang. PBMCs from normal individuals were isolated by density gradient centrifugation at 400xg for 25 minutes using Ficoll-Plaque Plus (Amersham Pharmacia Biotech AB, Uppsala, Sweden) and washed twice in PBS. Cells were maintained in RPMI + 10% FBS and supplemented with 10% FBS. Primary cells were obtained via written consent under the approval of the Dana-Farber Cancer Institute Institutional Review Board. The trypan blue dye exclusion test was previously described (Weisberg et al., 2002) and used to quantify PBMCs before seeding for the CellTiter-Glo Luminescent Cell Viability assay (Promega, Madison, WI). These assays were used for the studied growth and were performed according to the manufacturer's instructions. Cell viability is reported as a percentage of control (untreated) cells, and error bars indicate the standard deviation for each data point.

[0202] Ub-AMC assay The activity of USP7 and its variants was tested in Ubiquitin-AMC assays in and out of the presence of inhibitors. For this assay, USP7 catalytic domain WT or variants were used at concentrations of 250 nM USP7 WT, M407K, M407K / M410S or Q351S, 125 nM H461A, 600 nM Y514A, and 10 nM M410S. For the same assay, full-length USP7 WT and the Q351 variant were used at 50 nM. USP7 variants were pre-incubated with various concentrations of inhibitors or DMSO as a control in 50 mM HEPES pH 7.6, 0.5 mM EDTA, 11 µM ovalbumin, and 5 mM DTT. The reaction was incubated at room temperature for 30 minutes before adding 2 µM Ubiquitin-AMC (Boston Biochem) substrate. The initial reaction rate was measured by collecting fluorescence data at 30-minute intervals and 1-minute intervals using a Clariostar fluorescence plate reader at excitation wavelengths of 345 nm and emission wavelengths of 445 nm. The calculated initial rate values ​​were plotted against the inhibitor concentration, and IC50 was calculated. 50 The value of s was determined. All experimental data were plotted using Prism GraphPad. Figure 2A shows the optimization based on structural information for USP7 inhibition. Compound A (WO2013 / 030218), shown below, was optimized to arrive at compounds 10 and 11.

[0203] [ka] Figures 3A-3C show that compound 10 binds to USP7. Figures 4A-4D show the binding and dose-response inhibition of compounds A and 10. Figures 5A-5C show the microsomal stability and the USP7 binding ability of compound A and the compounds of this disclosure.

[0204] Table 3: USP7 activity of exemplary compounds in the USP7 assay. ++++ represents IC50 less than approximately 0.2 μM. 50 This indicates that +++ represents an IC with a size of approximately 0.2 μM to 1 μM. 50 This indicates that ++ represents ICs of approximately 1 μM to 10 μM. 50 This indicates that the + value is greater than approximately 10 μm of IC50 This indicates that the information is not disclosed. ND means that the information will not be disclosed. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] [Table 3-11] [Table 3-12] [Table 3-13] [Table 3-14]

[0205] Further example compounds include, but are not limited to, those given in Table 4 below. [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4]

[0206] Reference All publications and patents described herein are invoked by reference in whole, just as each individual publication or patent is invoked by reference specifically and individually. In case of any conflict, this application containing any definition herein shall be adjusted accordingly.

[0207] Equivalent forms While discussing specific embodiments of the invention, the above specification is illustrative and not limiting. Many variations of the invention will be apparent to those skilled in the art through the examination of this specification and the claims below. The complete scope of the invention should be determined by reference to the claims, along with the complete scope of equivalent forms, and by reference to the specification, along with the variations.

Claims

1. Formula I 【Chemistry 61】 (In the formula, R 1 , R 3 , and R 4 are each H; R 2 is a halogen, R 5 is —OH, R 6 is -C(=O)R 10 or -C(O)NR 7 R8, Each R 7 and R 8 is independently H, alkenyl or alkyl; said alkyl is substituted with one or more R 12 ; R 10 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, amino, heteroalkyl, alkylamino, aminoalkyl, or heteroaryl; said alkyl is optionally substituted with one or more R 13 ; The alkenyl and alkynyl each independently represent one or more R 13 optionally replaced by The cycloalkyl, heterocycloalkyl, aryl, and heteroaryl each independently represent one or more R 12 optionally replaced by Each R 12 is independently at each occurrence aryl or heteroaryl; wherein the aryl and heteroaryl are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, and -OH; Each R 13 is independently at each occurrence -OH, alkoxy, heteroalkyl, aryloxy, -NH 2 , cycloalkyl, heterocycloalkyl, -O-aryl, -O-heteroaryl, -NR 7 Aryl, -NR 7 Heteroaryl or -NR 7 C(=O)R 14 and The cycloalkyl, heterocycloalkyl and heteroalkyl are each independently alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -NO 2 and -OH, R 14 is alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl; The aryl and heteroaryl each independently represent one or more R 15 optionally replaced by the alkyl, alkenyl, and alkynyl are each independently optionally substituted with one or more substituents selected from halogen and -OH; Each R 15 is independently at each occurrence halogen, alkyl, CN-C(=O)alkyl, or -C(=O)alkenyl; the alkyl and alkenyl are each independently substituted with one or more substituents selected from halogen and -OH; n is 0 or 1; However, R 6 -C(=O)R 10 and R 10 is one R 13 (C 2 -C 3 ) alkyl, R 13 is not alkoxy or unsubstituted cyclopentyl, or a pharma- ceutically acceptable salt thereof.

2. 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein n is 0.

3. 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein n is 1.

4. R 2 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein is chloro.

5. R 6 -C(=O)R 10 2. The compound of claim 1, wherein:

6. The compound according to claim 1, or a pharma- ceutically acceptable salt thereof, wherein R6 is -C(O)NR7R8.

7. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R7 is H.

8. R 10 6. The compound of claim 5, or a pharma- ceutically acceptable salt thereof, wherein is alkyl, alkenyl, amino, alkylamino, alkynyl, cycloalkyl, heteroaryl, or aminoalkyl.

9. R 10 6. The compound of claim 5, or a pharma- ceutically acceptable salt thereof, wherein is heteroalkyl.

10. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein said aryl or heteroaryl of R10 is further substituted with alkyl, halo, alkyloxy, or nitro.

11. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein said aryl or heteroaryl of R10 is further substituted with halo, alkyloxy, or nitro.

12. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein said acylamino of R10 is substituted with halo, alkenyl, heteroaryl, or heterocycloalkyl.

13. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein said heteroaryl or heterocycloalkyl of R10 is substituted with alkyl acyl, alkenylacyl, or hydroxyl.

14. R 10 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl, wherein said alkyl is substituted with one or more R13, said alkenyl and alkynyl are each independently optionally substituted with one or more R13, and said cycloalkyl and heterocycloalkyl are each independently optionally substituted with one or more R12.

15. Each R 13 is independently at each occurrence -OH, aryloxy, -NH 2 , cycloalkyl or -NR 7 C(=O)R 14 15. The compound of claim 14, wherein:

16. Each R 14 16. The compound of claim 15, or a pharma- ceutically acceptable salt thereof, wherein, at each occurrence, is independently alkyl, haloalkyl, arylalkyl, alkenyl, heterocyclyl, or heteroaryl.

17. The compound 【Chemistry 62】 【Chemistry 63】 【Chemistry 64】 【Chemistry 65】 【Chemistry 66】 2. The compound of claim 1 ,

18. 【Chemical 67】 【Chemistry 68】 【Chemistry 69】 【Chemistry 70】 【Chemistry 71】 【Chemical 72】 or a pharma- ceutically acceptable salt thereof.

19. Formula I 【Chemical 73】 (In the formula, R 1 , R 3 , and R 4 are each H; R 2 is H, alkyl, haloalkyl, alkoxy, haloalkoxy, -OH, -NH 2 , -NO 2 , CN or -NR 7 R 8 wherein each alkyl is independently one or more R 9 optionally replaced by R 5 is —OH, R 6 is -C(=O)R 10 or -C(O)NR 7 R8, Each R 7 and R 8 is independently H, alkenyl or alkyl; said alkyl is substituted with one or more R 12 ; R 10 is alkyl, alkenyl, alkynyl, -NR 7 R 8 , cycloalkyl, heterocycloalkyl, aryl, amino, heteroalkyl, alkylamino, aminoalkyl, or heteroaryl; The alkyl, alkenyl and alkynyl each independently represent one or more R 13 optionally replaced by The cycloalkyl, heterocycloalkyl, aryl, and heteroaryl each independently represent one or more R 12 optionally replaced by Each R 12 is independently at each occurrence aryl or heteroaryl; wherein the aryl and heteroaryl are each independently optionally substituted with one or more substituents selected from alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, and -OH; Each R 13 is independently at each occurrence -OH, alkoxy, heteroalkyl, aryloxy, -NH 2 , arylalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-aryl, -O-heteroaryl, -NR 7 Aryl, -NR 7 Heteroaryl or -NR 7 C(=O)R 14 and The cycloalkyl, heterocycloalkyl, aryl, heteroalkyl and heteroaryl each independently represent alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, -NO 2 and -OH, R 14 is alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl; The aryl and heteroaryl each independently represent one or more R 15 optionally replaced by the alkyl, alkenyl, and alkynyl are each independently optionally substituted with one or more substituents selected from halogen and -OH; Each R 15 is independently at each occurrence halogen, alkyl, CN, -C(=O)alkyl, or -C(=O)alkenyl; the alkyl and alkenyl are each independently substituted with one or more substituents selected from halogen and -OH; n is 0 or 1; however, (i) R 6 -C(=O)R 10 and R 10 is one R 13 (C 2 -C 3 ) alkyl, R 13 is not unsubstituted cyclopentyl, unsubstituted phenyl, or unsubstituted 2-thiophenyl, (ii) R 6 -C(=O)R 10 If R 10 is not 1-ethylpropyl), or a pharma- ceutically acceptable salt thereof.

20. 20. A pharmaceutical composition comprising a compound according to any one of claims 1 to 19, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

21. A pharmaceutical composition for treating a disease or disorder modulated by USP7, comprising a compound according to any one of claims 1 to 19 or a pharma- ceutically acceptable salt thereof.

22. A pharmaceutical composition for treating cancer, comprising a compound according to any one of claims 1 to 19 or a pharma- ceutically acceptable salt thereof.